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INTRODUCTION 
 
Hepatitis C virus (HCV) is an enveloped, positive sense RNA virus of 9.6 kb belonging 
to family Flaviviridae and genus Hepacivirus (1,2). It has a single open reading frame 
(ORF), which encodes 3 structural proteins required for formation of the virus and 5 
non-structural proteins which serve as enzymes required for viral replication (3). 
Global prevalence of HCV is about 1%, with highest prevalence of 2.3% in East 
Mediterranean region (4). India has a prevalence of 0.09-2.02%, with about 6-11 million 
people infected with HCV (5,6). 
There are 7 confirmed genotypes of HCV and they are further classified into various 
subtypes (7). Genotype 1 predominates globally (8), while genotype 3 infects the 
majority in the Indian subcontinent (9). 
Being a blood borne virus, hepatitis C is transmitted mainly by sharing of contaminated 
needles among IV drug abusers (10) and transfusion of blood or blood products. 
Perinatal, occupational and sexual are other modes of transmission, though less frequent 
(11). 
It is a major cause of morbidity and mortality, with only about 15-25% of acute 
infections leading to resolution and the rest progressing to chronicity (12). It can 
multiply and form a niche for itself in the body and remain asymptomatic for years, 
with the symptoms appearing only when histological damage has occurred. Chronic 
liver disease, hepatic cirrhosis and hepatocellular carcinoma are the long term 
complications of this disease (13,14). Annually, hepatic cirrhosis accounts for more 
number of deaths (720,000 deaths) followed by hepatocellular carcinoma (470,000 
deaths). HCV infection is the underlying cause in 30% of these cases (4). 
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Hepatitis C virus infection can be diagnosed by Rapid Diagnostic Tests (RDTs) and 
serological tests such as Enzyme-Linked Immunosorbent Assays (ELISA) (15) and 
Chemiluminescent Microparticle Immunoassay (CMIA), which mainly detect the 
antibody response to such an infection. Serological tests, particularly RDTs are 
performed in low resource settings because of their wider availability. Nevertheless, 
these tests are not good predictors of current (active) infection as the antibodies begin 
to rise only later in the course of infection and persist for a long time. 
Molecular tests that detect and quantify HCV RNA are the gold standard, which if 
positive imply an active infection. They also help in monitoring response to therapy as 
the viral RNA decreases with effective therapy (16). 
Recently, HCV core antigen detection has also been employed as an alternative to HCV 
RNA quantification as it rises early in the infection and correlates well with HCV RNA 
levels, giving a better idea of level of replication of the virus or its decline (17,18). 
Genotyping of HCV is required, as currently the treatment and duration of therapy 
varies with different genotypes (19). 
PEG-IFN-α and ribavirin combination therapy were the preferred treatments for HCV 
a few years ago. With the advent of directly acting antivirals (DAAs), there is a 
possibility of cure. DAAs have shown an efficacy that is almost double to that of the 
previous regimens (20). Now, pangenotypic drugs such as sofosbuvir and velpatasvir 
have been licensed for use (21). 
Many people living in remote areas are still not aware that they have HCV infection and 
there is a dire need for better sampling and transportation of samples from such distant 
areas to reference centres, where the facility for diagnosis of HCV is available. 
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Globally, only about 1 million of the total 80 million population affected with HCV 
have access to treatment (22). DAAs are cost-effective, efficacious medications with 
less side effects which should become available to all individuals with demonstrable 
HCV viraemia even in the remote, less accessible areas of the country.  
Detection of HCV RNA and infecting genotype are required to start the treatment and 
assess the response. Collection of plasma and its appropriate transport to referral 
laboratories from distant resource-limited settings is challenging and may negatively 
impact on the accuracy of results. The challenges are due to duration of shipment and 
extremes of temperature that the clinical samples can be subjected to. 
Dried blood spots (DBS) have recently been evaluated as an alternative to plasma for 
detecting HCV RNA and HCV genotyping and it has been recommended in the recent 
WHO guidelines (23). 
There are not many studies evaluating DBS as a sample for HCV RNA detection in our 
country. Also the influence of extreme temperatures of the Indian subcontinent on such 
samples has not been addressed to. Our study aims at filling the lacunae in knowledge 
about feasibility of DBS as a means of collection, storage and transport for diagnosing 
and monitoring HCV infection. 
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AIMS AND OBJECTIVES 
 
AIM 
To assess the feasibility of dried blood spots as an alternative specimen to plasma for 
hepatitis C virus RNA detection and quantification, HCV genotyping and estimation of 
hepatitis C virus core antigen.  
 
 
 
 
 
OBJECTIVES 
1. To compare dried blood spots (DBS) with plasma as an alternative specimen source 
to detect/quantify HCV RNA, hepatitis C core antigen and to determine HCV genotype. 
2. To analyse the effect of different temperatures (4°C and ≥37°C for 15 days) on storage 
and transportation of DBS samples, prior to detection and quantification of HCV RNA, 
HCV core antigen and HCV genotyping. 
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REVIEW OF LITERATURE 
 
With the identification of non-A non-B viral hepatitis in the 1970s as a causative factor 
for transfusion related hepatitis, concerted investigations were undertaken and after 
employing molecular techniques, a novel infectious agent was identified in 1989; 
termed as hepatitis C virus (24,25). It was perceived to be a cause of hepatitis in blood 
donors (26), post transfusion patients, and intra-venous drug users (27). It can lead to 
acute infection or progress to chronicity in majority of patients (28) and can also be 
attributed to cirrhosis and hepatocellular carcinoma (29) after several years. 
1. Epidemiology 
1.1. Global Epidemiology 
The global prevalence of hepatitis C virus infection was 2.8% with >184 million people 
infected in 2005 (30). According to Global Hepatitis Report 2017 (WHO), its 
prevalence is about 1%, with about 71 million people living with chronic HCV infection 
as per estimates. Only 20% (14 million) of the population infected with HCV are 
diagnosed while the majority are still unaware of the infection (4). Highest prevalence 
(2.3%) is seen in Eastern Mediterranean region, followed by European region (1.5%) 
and African region (1%) (4). China with about 29.8 million people has the highest 
number of individuals infected with HCV, due to its largest population. It is followed 
by India (18.2 million), Egypt (11.8 million) and Pakistan and Indonesia with 9.4 
million each (31). Globally, it is known to be implicated in 26% of hepatocellular 
carcinoma and 28% of cirrhosis cases (32). Mortality due to chronic viral hepatitis is a 
matter of great concern. In 2015, 1.34 million deaths were attributed to complications 
of viral hepatitis, with HCV causing 30% of such deaths (4). 
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1.2. Indian Scenario 
Hepatitis C virus prevalence in India has been shown to vary from 0.09%-2.02% (6) 
and 6-11 million people are thought to be infected with HCV in India (5).  
Studies done in the northern part of India reported its prevalence as 5.2% in 2012 and 
3.2% in 2016 (33). Community based studies done in West Bengal found the 
seroprevalence of HCV to be 0.87% (34) and 1.5% (35). While, in the Western part of 
India the seroprevalence was 0.12% (36). Southern India shows a prevalence of 1.4% 
and 2.02% (37,38). S.A. Naik et al., in their study from one of the southern states of 
India found the prevalence to be 2.4% (39). In Vellore, a prevalence of 0.22% was 
observed by V. Gowri and colleagues, in a tertiary care centre (40). 
The various risk factors that have been ascribed for causation of hepatitis C virus 
infection are: (i) intravenous drug use: seroprevalance in such group of patients is about 
92%, (ii) multiple transfusions: 23.9%, 16.7 to 21% and 9.93% seroprevalence  in 
haemophilia patients, thalassemia patients and haemodialysis patients, respectively 
(41). Thus, it is imperative to follow safe injection practices to prevent the spread of 
HCV in India. 
 
2. Hepatitis C virus 
2.1. Taxonomy 
Hepatitis C virus is a positive sense RNA virus with an open reading frame which 
encodes for a polyprotein precursor of 3010 amino acids and belongs to Flaviviridae 
family because of sequence similarity to other Flaviviruses (1) and genus Hepacivirus 
(From greek word "Hepatos" meaning liver) (2). 
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2.2. Structure of virus 
HCV is roughly spherical, 55-65 nm in size, enveloped, 9.6 kilobase pairs long positive 
sense single stranded RNA virus. The RNA is enclosed in a nucleocapsid composed of 
core protein. Envelope has E1 and E2 glycoproteins.  
It contains a single large open reading frame encoding 3010 amino acids which forms 
various viral proteins after several modifications. The open reading frame is flanked by 
highly conserved 5' and 3' untranslated regions of 341 and 230 nucleotides, respectively 
(3).  
 
2.2.1. Untranslated regions 
The 5' untranslated region (UTR) is highly conserved region composed of 341 
nucleotides. It is here that an internal ribosomal entry site (IRES) is present which helps 
in initiating polyprotein translation by binding to 40S subunit of ribosome (3).  
The 3' UTR region consists of a 40 nucleotide long variable region, a poly U/UC tract 
which varies in its length from 30 to 80 nucleotides (42) and an X tail composed of 98 
nucleotides which are highly conserved (43). This region is important for viral 
replication and synthesis of negative strand RNA and it also forms a "kissing loop" with 
NS5b region, which is essential for viral replication (42). 
 
2.2.2. Polyproteins 
The single open reading frame (ORF) has 9024 to 9111 nucleotides, with the number 
of nucleotides varying with genotype. This ORF encodes a polyprotein with 3010 amino 
acids. This polyprotein is further cleaved into 10 proteins by post-translational 
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processing by the viral and cellular encoded proteases (44). The various regions of the 
ORF can be divided as follows: 
- Amino terminal end, encoding the structural proteins (Core, E1 and E2 
glycoproteins) 
- Central region encoding p7 and NS2 proteins, which are essential for virus 
production 
- Carboxy terminal end which encode the non-structural proteins such as NS3, 
NS4A, NS4B, NS5A and NS5B. 
The various proteins are designated based on their molecular weight, as depicted in the 
following figure. Core antigen has a molecular weight of 22 kilo daltons and expressed 
as p22. NS1 protein is referred as p7 widely in the literature (45). 
 
Figure 1: Open reading frame of HCV genome with the proteins produced. 
Adapted from Ashfaq et al., 2011 (44) 
 
2.2.2.1. Structural proteins 
i. Core protein: It is a highly conserved basic protein which forms the 
nucleocapsid of the virus. It consists of 191 amino acids and is classified into 
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three domains i.e. domain 1 (amino acid 1-117), which is formed mainly of basic 
residues, domain 2 (amino acid 118-174) and domain 3 which is highly 
hydrophobic (175-191 amino acids) (44). Core antigen (p22) is released into the 
plasma during viral replication (46), which is used in diagnosis of HCV infection. 
ii. E1 & E2 glycoprotein: These are highly glycosylated envelope proteins, which 
help in entry of the virus into the cell. E1 helps in fusion of the virus to the cell 
while E2 serves as receptor binding subunit (44). There is more genetic diversity 
in these proteins with respect to the different genotypes of HCV (47). 
In addition, E2 envelope glycoprotein has a hypervariable region, which helps in 
evasion of neutralisation by antibodies (47). 
 
2.2.2.2. p7 and NS2 proteins 
These two proteins are not essential for replication but are important for release of 
virions. The p7 protein acts as an ion channel and is supposed to be involved in calcium 
ion transport (48). It has also been shown to confer infectivity to hepatitis C virus (49). 
NS2 is a non-structural protein which acts in tandem with amino terminal of NS3 to 
form a NS2-3 protease (50,51). It loses protease activity after being dissociated from 
NS3 and is degraded by protein kinase casein kinase II (52). 
 
2.2.2.3. Non-structural proteins 
NS3, NS4A, NS4B, NS5A, NS5B constitute the remaining non-structural proteins of 
HCV. NS3 protein has a helicase as well as a serine protease domain and it acts along 
with NS4A (a cofactor) to cleave the viral polyprotein at NS3/NS4A, NS4A/NS4B, 
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NS4B/NS5A and NS5A/NS5B junctions. NS4B causes changes in the morphology of 
endoplasmic reticulum and serves an important function in viral replication (53). NS5A 
protein has transcription activation functions (54) and has even been shown to be a 
cause of interferon resistance (55). NS5B serves as an RNA dependent RNA 
polymerase and is a target for many new antivirals against HCV (56). 
 
2.3. Replication 
HCV gets attached to the host cell with the help of E1 and E2 glycoproteins. CD81, 
scavenger receptor class B type 1, CLDN 1, 6 and 9, mannose binding lectins such as 
DC-SIGN and L-SIGN have been identified as potential receptors for hepatitis C virus 
on the host cell surface (44).  
Virus is then internalised into the host cell, RNA genome is released in the cytoplasm 
(57) and the positive sense RNA serves as mRNA and initiates translation of polyprotein 
after binding of IRES to the 40S ribosomal subunit. This translation occurs at the 
endoplasmic reticulum membrane and a "membranous web" is formed as a result (58). 
HCV also recruits certain host cell proteins such as phosphatidylinositol 4-kinase III 
(PI4KIII) for its replication (59). RNA dependent RNA polymerase synthesises 
negative stranded RNA, which forms the positive strand RNA again and a "replication 
complex" is formed near the nuclear membrane. Encapsidation of genome occurs in 
endoplasmic reticulum and the virus is enveloped in the golgi apparatus of the host cell 
and released by exocytosis after the process of maturation and assembly is complete 
(60).  
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2.4. Genetic diversity: 
2.4.1. Quasispecies  
NS5B RNA polymerase lacks proof reading activity and thus HCV replication is 
susceptible to errors and mutations. This results in accumulation of a host of closely 
related but still distinct HCV variants in the infected individual, called quasispecies 
(61). This might result in selection of treatment resistant mutants, resulting in reduced 
efficacy of new anti-viral therapies (62). 
 
2.4.2. HCV genotypes 
There exists enormous heterogeneity among sequences of HCV isolated from different 
individuals, which is over and above the quasispecies found in an individual infected 
with hepatitis C. There are 7 confirmed genotypes of HCV. These genotypes are further 
classified into 67 subtypes, 20 provisionally assigned subtypes and 20 subtypes which 
are still unassigned (7). Each of the genotypes differ from each other by about 30-35% 
of nucleotides, while related subtypes vary by about 20% in sequence homology and 
the variation is 10% in the different isolates of same genotype (63). Hepatitis C virus 
genotyping is carried out by sequencing specific regions of the virus, such as 5' UTR, 
Core, E1 and NS5b (64,65). The different genotypes differ in their susceptibility to 
various drugs and antiviral agents and thus the therapy needs to be modified according 
to the genotype (66).  
2.4.2.1 HCV genotypes: Global distribution 
Genotype 1 is the most common (44%) prevalent genotype worldwide. It is followed 
by genotype 3 and genotype 4 with the prevalence being 25% and 15%, respectively 
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(8). Genotype 1 is seen mostly in high income countries such as USA and northern 
Europe. Genotype 2 is seen mostly in Japan, Europe and North America. Genotype 3, 
even though worldwide in distribution, is detected predominantly in South Asia and the 
Indian subcontinent. Genotype 5 is mainly limited to South Africa and genotype 6 is 
predominantly seen in Australia and the far east (64,67). Genotype 7 was first identified 
in Canada from an African patient and has since been identified in a handful of patients 
from Democratic Republic of Congo (68). 
 
2.4.2.2. HCV genotypes: Indian scenario 
As is aforementioned, genotype 3 is most prevalent in the Indian subcontinent. 
Amarapurkar D et al., in 2001 showed the prevalence of genotype 3, genotype 2 and 
genotype 1 to be 54%, 25% and 21%, respectively (9).  
The prevalence was shown to be 63.38% for genotype 3, 30.98% for genotype 1 and 
5.63% for genotype 2 in the study done by Anita Chakravarti and colleagues in 2011. 
In the study spanning over a decade and a sample size of over 450 patients undertaken 
by Christdas et al., the prevalence of genotype 3 was 63.85%. The prevalence of 
genotype 1, genotype 4 and genotype 6 was 25.72%, 7.5% and 2.7%, respectively (69). 
Genotype 3 was predominantly seen in Eastern and Northeastern India while South 
India had preponderance of genotype 1, followed by genotypes 3 and 4. Genotype 4 
was seen mostly in patients from South India while genotype 6 was prevalent in patients 
from North Eastern states of India (70,71). Genotype 2 was seen only in a single patient 
throughout the duration of the study and no cases of HCV infection with genotype 5 
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were observed. A recombinant strain of HCV genotype 1b and 2k was also seen in 2 
patients during the duration of study (69). 
In a study from Kolkata by Chaudhuri et al., prevalence of genotype 3 was 79.8% while 
genotype 1 was 10.2% and genotype 2 was 3.8% (72). Similarly, study from Northern 
India showed highest prevalence of genotype 3 i.e. 80.2%, followed by genotype 1, 
genotype 4 and genotype 2 with 13.1%, 3% and 2.5%, respectively (73). 
 
3. Transmission of hepatitis C virus infection 
Hepatitis C virus is one of the most important blood borne viruses to cause a chronic 
infection, leading to death in a certain subset of patients (74). The most common route 
of HCV transmission is through sharing of contaminated needles by intra-venous drug 
users with 15-30% of such people acquiring hepatitis C virus infections (10). Global 
prevalence among people who inject drugs is around 67% (75) . It is followed closely 
by cases of transfusion of blood or blood products mainly in people requiring multiple 
transfusions; such as patients with haematological disorders and patients on dialysis 
with such patients accounting upto 40% of the global burden of HCV (76). Other routes 
of transmission of HCV are occupational exposure (risk of about 0.2-10% after needle 
stick injury), perinatal (in 3-10% cases) (77) and unsafe sexual practices (11). 
 
4. Clinical course of HCV infection 
i) Acute infection 
Hepatitis C virus has an incubation period ranging from 2 months to 6 months. Acute 
infection with HCV is mostly asymptomatic. During the acute infective phase HCV 
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RNA is detectable for the first 2 weeks. Later on, an elevation in the liver enzymes is 
seen from 2-8 weeks. Symptoms of hepatitis namely malaise, fatigue, right upper 
quadrant pain, nausea, dark urine and jaundice can be observed in about 25-30% of 
patients within 3-12 weeks of acquiring HCV. Anti-HCV also appears in the patients 
by about 7-8 weeks after infection, with delayed seroconversion seen in a group of 
patients (78). 
Spontaneous resolution which is defined as undetectable HCV RNA in blood is seen in 
about 15-25% patients, while the rest progress to chronicity (12). 
 
ii) Chronic infection 
Chronic HCV infection is defined as persistence of HCV RNA in blood of the patient 
for 6 months or more. The various factors that influence the progress to chronicity are 
age at the exposure, male sex, race, co-infections and host factor such as the immune 
status of the patient (12). Patients with chronic hepatitis C infection are predominantly 
asymptomatic but have raised serum transaminases, which can fluctuate over time. Only 
6% of patients might have symptoms. Fatigue, nausea, abdominal pain and decreased 
appetite are the common symptoms. The disease can remain clinically silent for decades 
while hepatic inflammation and fibrosis continue in the liver. The factors influencing 
hepatic fibrosis are alcohol consumption, age at the time of infection, male gender, 
immunosuppression, obesity and insulin resistance (79,80). Hepatic cirrhosis occurs in 
about 5-20% of patients after 20-30 years with 10 year survival rate for such patients 
being 80% (81).  
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Cirrhotic patients are at a higher risk of developing decompensated liver disease and 
hepatocellular carcinoma (HCC), with about 1-4% of such patients progressing to HCC 
every year (13,14). 
 
 
5. Extra hepatic manifestations of HCV 
HCV infection can also result in certain extrahepatic manifestations in about 40-74% 
of patients. Mixed cryoglobinemia is the most common among them.  
Other manifestations are non-Hodgkin lymphoma and porphyria cutanea tarda. 
Metabolic disorders such as insulin resistance and steatosis can also be seen in a certain 
group of patients (13). 
6. Immune response to hepatitis C virus infection 
Pathogen associated molecular patterns (PAMPs) are the moieties present on the 
infective virions which are recognized by their corresponding receptors on the host cell, 
resulting in initiation of an immune response. The pathways triggered by viral infection 
are either toll-like receptor dependent pathway or the cytosolic pathway involving RIG-
1 (retinoic acid inducible gene-1). This results in activation of NF-kB and interferon 
Figure 2. Natural history of HCV infection. Adapted from Di Bisceglie et al. (14)  
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regulatory factors which ensues in production of interferons by activation of interferon 
stimulator genes, thus resulting in initiation of antiviral response of the body (82).  
HCV is known to evade immune response of the host and to survive for a longer 
duration resulting in disease progression. 
 
6.1. Innate immune response 
First line of defence to any infection is innate immunity. Interferons act as mainstay for 
innate immunity. It induces an antiviral state and activates the natural killer cells. Cells 
infected with viruses give rise to type I and type II interferons, while NK cells produce 
interferon-γ.  
Hepatitis C virus infection leads to initiation of TLR and RIG-1 pathways which 
culminate in activation of IRF3 (Interferon regulatory factor 3). This IRF3 along with 
NF-kB initiates transcription of interferons which bring about an antiviral state in 
nearby cells. Type I and type III INFs are produced in the early acute phase of hepatitis 
C infection and are capable of controlling viral replication upto a certain extent but not 
of eliminating it (82). Interferons bind to their specific receptor and cause activation of 
Janus kinase/Signal transducer and activator of transcription (Jak-STAT) pathway. As 
a result, interferon-stimulated genes (ISGs) are induced which have antiviral properties. 
RIG -1 and interferon regulatory factor 7 (IRF-7) also function as ISGs and promote 
interferon production (82).  
Natural killer cells also play a major role in acute HCV infection. NK cells mediate 
direct antiviral effects by tumour necrosis factor (TNF)-related apoptosis-inducing 
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ligand (TRAIL) or perforin mediated (direct cytolytic) and IFN-γ mediated (non-
cytolytic) pathways (82). 
Ubiquitin molecules also play a role in controlling HCV infection. IFN type I induces 
E3 ubiquitin ligase tripartite-motif 22 (TRIM22), which is thought to be associated with 
response to treatment by peg-IFN-α-2a/RBV therapy (83). 
 
Figure 3. Course of HCV infection. Adapted from Heim and Thimme, 2014 (82) 
 
6.2. Attenuation of innate immunity of host by hepatitis C virus 
The various mechanisms by which HCV attenuates the host's innate immunity are (84): 
a) Protease activity of HCV NS3/4A results in cleavage of toll-IL-1 receptor 
domain containing adapter inducing IFN-β (TRIF) and IFN-β, thus blocking 
RIG-1 signalling and ablating TLR3 signalling, culminating in decreased IRF3 
activation. 
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b) HCV core protein can increase the level of suppressor of cytokine signalling 
protein 3 (SOCS-3), which in turn act as inhibitors of Jak-STAT pathway and 
form a negative feedback loop decreasing IFN-α/β receptor signalling. 
c) NS5A protein of HCV stimulates IL-8, which causes attenuation of ISG 
expression and antagonisation of type I IFN signalling. 
 
Figure 4. Evasion of Innate immune response by HCV. Adapted from Barbara 
Rehermann (2009) (85) 
 
6.3. Adaptive immune response 
6.3.1. Humoral immunity 
Antibodies to hepatitis C virus are detectable in the blood by about 7-8 weeks after 
infection. These are specific for an isolate and exert a selection pressure leading to 
evolution of various quasispecies. Although, there is no clear role of humoral response 
in controlling the infection that has been elucidated; it has been proven that antibodies 
have a limited effect on regulating HCV infection. Presence of antibodies during early 
19 
 
phase of infection has even shown to be associated with spontaneous clearance of 
hepatitis C virus from the body (86). 
It is mainly the hypervariable region 1 (HVR1) of E2 that has been shown to lead to 
persistence of infection. Antibodies which target a more conserved region, other than 
HVR 1 have been shown to result in virus clearance (87). 
A lack of robust immune response and antibodies during the early phase of infection 
can lead to chronicity. Increased severity, rapid progression of disease and chronic 
illness is seen in patients with less antibodies, thus suggesting that these antibodies play 
a crucial role in HCV disease progression (88). 
 
6.3.2. Cell mediated response 
CD8+ and CD4+ T-cell response specific to HCV are of critical importance in 
suppression and clearance of HCV infection. Patients who spontaneously recover and 
clear the infection are shown to have increased levels of IL-2 and IFN-γ, which are 
formed by the HCV specific CD4+ cell. In patients who develop chronic infection, the 
HCV specific CD4+ cell responses are weak or absent (85).  
CD8+ cells specific to HCV are detected in blood of patients in acute phase of HCV 
infection. These cells produce cytokines such as TNF-α and IFN-γ and even result in 
cytolysis of HCV infected cells. IFN-γ secreting CD8+ cells are seen predominantly in 
people who recover from hepatitis C virus infection (89). Impaired CD4+ cell function 
leads to exhaustion of CD8+ cells. There is loss of cytolytic activity of the CD8+ cells, 
as well as a substantial decrease in TNF-α and INF-γ production. As a consequence 
chronic HCV infection develops (85). 
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6.3.3. Evasion of humoral and cellular immune response by hepatitis C virus 
HCV causes a chronic infection in majority of the patients. It does so by evading the 
immune response of the body by following mechanisms (84,90,91): 
a) Mutation in epitopes of hepatitis C virus 
NS5b protein of HCV which acts as RNA dependent RNA polymerase has a 
lesser proof reading capability and is prone to errors. Such errors result in 
formation of mutational variants which have certain differences in their epitopes 
enabling them to evade the cellular immune response. 
b) Anergy of CD8+ cells specific to HCV 
CD8+ cells loose there specificity for HCV overtime, which might help the virus 
in evading the immune response.  
c) Populations of regulatory T-cells 
CD8+ T cells present in the liver of an individual infected with HCV are known 
to produce interleukin-10. IL-10 downregulates effector T cells and hampers the 
production of IFN-α. Moreover, CD4+CD25+ regulatory T cells are also 
observed in chronically infected patients. 
d) T cell inhibitory receptors 
PD-1 (Programmed death-1) is a T cell inhibitory receptor. Levels of surface PD-
1 are found to be significantly higher in people who develop chronic HCV 
infection (90). Thus, this can also be considered as a mechanism of evasion by 
the hepatitis C virus. 
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The various mechanisms of evasion of adaptive immune response by HCV is depicted 
as follows: 
 
Figure 5. Mechanisms of evasion of adaptive immune response by HCV. Adapted 
from Burke and Cox (90) 
 
7. Diagnosis of HCV infection 
Hepatitis C virus infection testing is advised in symptomatic patients with a suspicion 
of underlying liver disease, in individuals belonging to high risk groups and as a 
mandatory screening procedure for blood donors in blood banks (since 2002). WHO 
guidelines for testing of HCV infections published in February 2017 recommends 
22 
 
testing in adults and adolescents from population with high HCV burden and in all 
individuals with a high clinical suspicion of viral hepatitis (23). In addition, focused or 
targeted testing in specific high risk groups such as IV drug users, prisoners, MSM and 
sex workers, HIV infected individuals, family and close contact of already infected 
cases and health care workers should be undertaken (23,92). 
The various tests that are available for diagnosing hepatitis C virus can be grouped into: 
i. Rapid diagnostic tests (RDTs): Based on detection of antibodies to HCV by 
immunofiltration or "flow through technology" (93). 
ii. Serologic tests: Antibodies to HCV are detected by using recombinant antigens 
by ELISA and CMIA methodologies. Recently, HCV core antigen has also been 
added in certain CMIA and ELISA formats. 
iii. Molecular tests: Nucleic acid amplification tests are employed for detection and 
quantification of HCV RNA and genotyping of HCV. 
iv. Other tests: Liver function tests, fibroscan, acoustic radiation force impulse 
(ARFI), AST to platelet ratio index (APRI) and liver biopsy. 
 
7.1. RDTs (Rapid diagnostic tests) 
Rapid diagnostic tests can be used as point of care tests and may be employed as a 
preliminary diagnostic test in low resource settings, as no elaborate procedures are 
required and results are available within minutes.  
These tests are based on immunochromatographic, immunofiltration and "flow through 
technology". Highly purified HCV antigens from core, NS3, NS4, NS5 regions are 
immobilised on the strip and the patient's sample is added, which if contains antibodies 
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to those antigens will give a positive reaction. The sensitivity of such tests are lower 
than that of ELISA (93). 
 
7.2. Serological tests (ELISA and CMIA) 
a) Detection of antibodies 
Antibodies to hepatitis C virus can be detected in patients by 1-2 months of infection. 
ELISA which employs the principle of enzymatic reaction to ascertain antibodies in a 
patient's sample can be used. There are various generations of ELISAs that have evolved 
over a period of time. First generation ELISA uses c100-3 part of NS4 genome of HCV 
as the antigen. Lower sensitivity of first generation ELISA led to the development of 
2nd and 3rd generation ELISAs. To add to the sensitivity of the assay, c22-3 and c200 
proteins were used additionally in 2nd generation ELISA. NS5 protein were the addition 
in third generation ELISA (15). Recently, combination ELISAs have come into the 
market which have antibodies to core antigen coated on the microtitre wells, so 
antibodies and core antigen can be detected resulting in higher specificity. 
Chemiluminescence immunoassay, such as Abbott ARCHITECT platforms utilises 
microparticles on which the recombinant antigens or antibodies are coated for detection 
of corresponding elements in the patient's sample.  
RIBA (Recombinant immunoblot assay) was another type of test to detect specific 
antibodies in the patient's sample. In this, recombinant antigens of HCV (namely, 
recombinant c33c and NS5 antigens and synthetic 5-1-1, c100 and c22 peptides) were 
coated on a nitrocellulose membrane and a conjugate and substrate were added after 
addition of patient's sera to give coloured bands (94). It was a strip immunoblot assay 
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(SIA) where no bands meant a negative result, one band indicated indeterminate result 
and a minimum of two bands were taken as positive (95). 
b) Detection and quantification of HCV core antigen 
Hepatitis C virus core antigen is a highly conserved structural protein of 191 amino 
acids in length. It can be detected in blood during viral replication. The advantage of 
estimating core antigen is that it is positive even during the pre-seroconversion window 
period, in immunosuppressed individuals and in neonates where the antibodies to HCV 
are negative (17). A positive result confirms active infection. There are various 
combination ELISAs available for detection of HCV core antigen along with antibodies 
in the patient's sample (96). Chemiluminescence assays with microparticles coated with 
monoclonal antibody to HCV core antigen can also be employed for its detection. 
Sensitivity ranges from 80-99%, while specificity is about 96-100% (18,97). It is a 
simple and cost-effective method to establish active HCV infection in settings where 
the facilities for molecular tests are absent. The only limitation with core antigen 
detection is that for core antigen to be detectable in plasma, HCV RNA value should be 
1000 IU/mL. 
7.3. Molecular tests 
7.3.1. HCV RNA detection 
Detection of viral nucleic acid is essential to establish active infection. Apart from being 
the confirmatory test of hepatitis C virus infection, HCV RNA detection also serves as 
a mainstay of diagnosis in neonates and immunosuppressed patients. Branched-DNA 
assay, transcription mediated amplification (TMA), reverse transcriptase polymerase 
chain reaction (RT-PCR) and real time PCR are the various methods used to detect and 
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quantify HCV RNA (98,99). With the discovery of antiviral agents, there has been an 
immediate need to quantify HCV RNA for monitoring therapy and response to 
treatment. Viral RNA is measured in "International Units" (IU) instead of viral copy 
numbers, according to the WHO. The viral copies/mL= viral load in IU/mL X 2.7 (for 
Roche COBAS TaqMan). Newer assays have lower limit of detection ranging from 12-
50 IU/ml and specificity of 98-99% (16). 
 
7.3.2. Genotyping 
7.3.2.1. HCV genotyping 
Treatment of HCV depends on the genotype of the virus infecting the individual. 
Certain genotypes such as genotype 1, require a prolonged duration of treatment. In the 
recent past, pegylated-IFNα and ribavirin were in use for treatment and now directly 
acting antivirals (DAAs) are the mainstay of treatment. Different treatment regimens 
and duration are advised for each genotype, thus necessitating the role of HCV 
genotyping (100,101).  
Genotyping can be performed by sequencing core, 5'UTR, NS3 or NS5b regions of 
hepatitis C virus (19). Line probe assay i.e. reverse hybridisation of amplified products 
on probes specific for genotypes, PCR-restriction fragment length polymorphism 
(RFLP) in which amplicons are digested by help of restriction enzymes to yield 
fragments specific to different genotype are other methods used to genotype HCV. 
Recently, real-time PCR with specific primers and probes for different genotypes have 
also become available (102). 
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7.3.2.2. IL-28B genotyping 
Interleukin-28B gene (rs12979860 and rs8099917) polymorphisms predict sustained 
virological response (SVR) in patients. Thus, detection of such single nucleotide 
polymorphism is important for ascertaining the prognosis after treatment (103). 
Genotyping of IL-28B region which is present on chromosome 19 is performed by 
RFLP or sequencing.  
 
7.4. Other tests 
Liver function tests, fibroscan, acoustic radiation force impulse (ARFI) test can also be 
of use to detect any pathology in the liver. Aspartate transaminase to platelet ratio 
(APRI) is a new score to assess the degree of liver fibrosis (104). Liver biopsy is 
recommended to stage the degree of hepatic necrosis, fibrosis and inflammation but is 
generally not preferred, as it is an invasive procedure (105).  
 
8. Treatment  
8.1. Rationale for treatment 
HCV infection is a significant cause of morbidity and mortality. It results in chronic 
infection in about 80% of patients. Most of these infections are asymptomatic and 
slowly progress towards liver cirrhosis and hepatocellular carcinoma. Even in absence 
of significant hepatic symptoms, severe extra hepatic symptoms can predominate. Thus, 
treatment of hepatitis C virus becomes a necessity. With the introduction of DAAs in 
the past few years, there is a possibility of cure. Antiviral treatment is helpful in 
preventing the progress of the hepatic disease, as well as in providing a respite from 
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extra-hepatic manifestations of HCV. Virus clearance takes upto 24 weeks after starting 
effective therapy. Sustained virological response (SVR) refers to absence of virus (HCV 
RNA) in the patient 12 or 24 weeks after completion of therapy and it is considered as 
a measure of effectiveness of the drug regimen (106). Timely and effective treatment 
can reduce the chances of complications of chronic HCV infection and reduce the liver-
related mortality (107).  
 
8.2. Anti HCV drugs 
1) Interferon and ribavirin combination therapy 
Interferon-α was the mainstay of treatment of chronic hepatitis C for more than two 
decades. Even though it was not very effective, it resulted in viral clearance in about 
10-25% of patients (108). INF-α and ribavirin combinations were in use since the late 
1990s. This combination resulted in almost two fold increase in virological response. 
Pegylated interferons were introduced in early 2000s and because of less side effect 
profile compared to interferons, its combination with ribavirin has been in use since 
then. The duration of therapy varies with the genotype of hepatitis C virus infecting the 
patient. Genotypes 2 & 3 require a shorter duration i.e. 24 weeks, while genotypes 1, 4, 
5 and 6 infections require longer duration of therapy (109). 
2) Directly acting antivirals (DAAs) 
With the sustained virological response being only about 40% even after 48 weeks of 
therapy with peg-INF-α and ribavirin combination therapy for patients infected with 
HCV genotype 1, finding suitable and more effective drugs for treatment was the need 
of the hour. Directly acting antivirals, targeting the viral proteins involved in life cycle 
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of HCV have been developed in the recent years. The first drugs to be approved were 
boceprevir and teleprevir, which act on NS3/4A protease and bring about its inhibition 
(20). The use of these drugs in the combination with the existing therapy showed a 
marked increase in the virological response but did not help in the management of 
people who had failed a previous interferon therapy. Adverse effects such as severe 
anaemia and hypersensitivity reactions were also observed with these drugs and 
consequently these were removed from the market (110). Since then, other new DAAs 
such as sofosbuvir, ledipasvir, daclatasvir etc. have been introduced in HCV treatment 
regimens as these have better tolerability, better safety profile and a SVR of more than 
95% after the completion of regimen (111). 
 
8.3. Interferon and ribavirin combination therapy 
There have been constant revisions in the treatment guidelines of HCV over the past 
few decades. Newer drugs have been added and duration of therapy has been revised. 
The various regimens and drug combinations in use for the treatment of HCV in the 
past few decades have been outlined below: 
 
i. Interferon-α monotherapy 
Interferon-α has been shown to be effective in patients with HCV infection since 
early 1990s (108,112). Interferons stimulate ISGs through various cascades and 
have an immunomodulatory effect resulting in increased cytokine production 
and activation of natural killer cells which leads to antiviral effect. It was the 
mainstay for treatment of chronic hepatitis C infection for almost a decade. 
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However, with severe adverse effects such as neutropenia, myalgia, 
neuropsychiatric manifestations, fatigue (113) etc. and with sustained virological 
response ranging from 10-25% in patients, this was used in combination with 
ribavirin. 
ii. Interferon-α and ribavirin combination 
Ribavirin is a guanosine analogue, synthesised in 1970 and was used in treating 
respiratory syncytial virus infection in children. It had a broad antiviral spectrum 
and thus was introduced as a combination therapy along with interferon-α for 
treatment of chronic hepatitis C. The use of ribavirin as a combination drug lead 
to almost doubling of rates of sustained viral response (114). The various 
mechanisms of action postulated for ribavirin are (115): 
a) Inhibition of replication of HCV: Ribavirin is a guanosine analogue and can 
be incorporated in the viral RNA in its phosphorylated state. This brings about 
chain termination and inhibition of HCV replication. 
b) Inosine-monophosphate-dehydrogenase inhibition: Ribavirin competitively 
inhibits inosine-monophosphate-dehydrogenase which leads to GTP depletion. 
GTP is vital for viral RNA synthesis and this inhibits HCV replication. 
c) Mutagenesis: According to Crotty S. et al., ribavirin can act as a viral mutagen 
and result in formation of virions with decreased infectivity (116,117). 
iii. Pegylated interferon-α 
Pegylated interferon-α is formed by covalent conjugation of monomethoxy 
polyethylene glycol (PEG) with interferon-α. It was introduced in early 2000s 
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(100). PEG-INF-α has a better pharmacological profile compared to INF-α and 
results in a higher SVR rate reaching upto 82% (118,119). Recent studies have 
shown higher incidence of adverse effects and mortality on use of PEG-
interferon-α and ribavirin combination regimen (120). 
8.4.1. Directly acting antivirals (DAAs) 
Combination therapy with pegylated interferon-α and ribavirin were not effective with 
SVR rates hovering around 40% in certain cases. This necessitated the search for newer 
compounds which were better tolerated and had better SVR rates. Ciluprevir (BILN-
2061) was the first drug to be tested but was withdrawn after severe side effects were 
observed in animals (121). Serine protease inhibitor therapy trial 2 (SPRINT-2) was 
undertaken to assess boceprevir, a newer drug targeting the NS3 region of HCV. Triple 
regimen therapy with PEG-IFN-α, ribavirin and boceprevir resulted in a SVR rate of  
68% after 24 weeks of therapy, which was significantly higher than the existing dual 
drug combination therapy of PEG-IFN-α and ribavirin (122); thus heralding a new era 
of directly acting antivirals.  
In early 2010s new oral drugs were approved for the treatment of chronic hepatitis C 
infection. The first such drugs were the protease inhibitors (boceprevir and teleprevir), 
which target the NS3/4A region of HCV genome (123). Since then, several other drugs 
targeting other regions such as NS5A and NS5B of hepatitis C virus have been 
introduced in therapeutic regimens for HCV.  
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Figure 6. Timeline of development of DAAs. Adapted from Akihiro Tamori et al. 
(124) 
 
The classification of directly acting antiviral drugs for HCV with the profile and 
mechanism of action for each drug are elucidated as following (125): 
a. Protease Inhibitors: NS3 protein of HCV has protease function and NS4 
protein acts as a cofactor to aid in the protease and helicase function of NS3/4A. 
NS3 exhibits protease activity at the amino terminal and helicase activity at the 
carboxy terminal. Substrate attaches to a shallow cleft present between the two 
terminals. Teleprevir and boceprevir are the prototype drugs of this class. 
Simeprevir, grazoprevir, paritaprevir are other drugs belonging to this class 
(126). Asunaprevir, voxileprevir and glecaprevir are currently under clinical 
trials (127). 
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Antiviral property is because of direct inhibition of HCV replication by 
inhibition of protease function and indirect effect by inhibition of cleavage of 
TRIF and mitochondrial antiviral signalling protein (MAVS) adaptor molecules 
by NS3/4A in TLR3 and DDX58 pathways resulting in increased INF-β (128).  
Adverse effects such as rash and hematopoietic suppression is common with this 
class of drugs, owing to which boceprevir and teleprevir were withdrawn from 
the market by the end of 2015 (129). 
 
b. NS5B inhibitors: This class of compounds bind to NS5B protein of HCV which 
serves as a RNA dependent RNA polymerase. This NS5B polymerase is 
composed of about 590 amino acids and has a right hand topology with palm, 
thumb and finger regions. NS5B inhibitor drugs bind at the substrate site of the 
polymerase and bring about inhibition of viral replication.  
These NS5B inhibitors can be further classified as nucleotide and non-nucleotide 
inhibitors (130). Non-nucleotide inhibitors (NNIs) such as dasabuvir and 
beclabuvir bind to allosteric site on NS5B and induce a confirmational change 
in the RNA dependent RNA polymerase with a resultant blockage of enzymatic 
activity.  
Sofosbuvir is the prototype drug belonging to nucleotide inhibitor class. It is a 
uridine analogue, administered in the prodrug form and needs to be changed to 
its active triphosphate form to bind to NS5B protein. It competes with natural 
nucleoside triphosphate and prevents the replication of RNA (125). Sofosbuvir 
shows pangenotypic activity and has a high barrier to resistance. 
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Nausea, diarrhoea, flatulence, headache and rash are the common side effects of 
this class of drugs (131). 
 
c. NS5A inhibitors: NS5A is a phosphoprotein of 44 amino acids with three 
domains. It is essential for replication of HCV and for morphogenesis of virions, 
with its specific role not yet known (125).  
NS5A inhibitors are proposed to inhibit membranous web formation, which is 
essential for viral replication. In addition, these inhibitors may form complexes 
with host factors such as TIP47 (Tail interacting protein of 47 kD) or PI4KIIIα 
and adversely affect viral replication and assembly (132). Daclatasvir was the 
first NS5A inhibitor produced. Ledipasvir, ombitasvir and elbasvir are newer 
compounds of this class. Velpatasvir is a widely used pangenotypic drug 
belonging to this class of drugs (133). 
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Figure 7. Site of action of directly acting antivirals. Adapted from Gotte and Feld 
(125) 
 
8.4.2. DAAs: treatment regimens 
Direct acting antivirals have a high tolerability and compliance due to once daily oral 
dosage, less severe side effects and lead to a SVR reaching upto 95% (134). These 
DAAs are generally advised as a combination of two drugs to achieve a high sustained 
virological response (SVR). Ribavirin can also be included in the combination therapy. 
The dosage of various drugs for the treatment are (135): 
Sofosbuvir: 400 mg/day in 1 dose {Or in combination with ledipasvir & velpatasvir} 
Ledipasvir: 90 mg/day in 1 dose  
Daclatasvir: 60 mg/day in 1 dose 
Ribavirin: 1000 mg at body wt. <75 kg, 15 mg/kg in children 
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WHO recommended regimens for the treatment of hepatitis C virus infection for the 
year 2016, adapted from “American Association for the Study of Liver Diseases 
(AASLD) and European Association for the Study of the Liver (EASL)" (136): 
 
Figure 8. Recommended regimens for HCV treatment. Adapted from WHO 
guidelines, 2016 (136). 
8.4.3. Resistance to DAAs 
Resistance to directly acting antivirals is a relatively new phenomenon observed in 
individuals who don't achieve SVR even after completion of the full duration of therapy 
(137). The various mechanisms suspected to be involved in resistance to DAAs are 
(138): 
a) Quasispecies:  Presence of a large number of viral variants in the individual because 
of high error rate and lack of proof reading ability of NS5B protein of HCV. This can 
result in selection of variants with mutations favouring survival of the virus. 
b) Nucleotide polymorphisms and mutations: S282T, L159F and V321A are certain 
mutations that have been observed in patients non-responsive to sofosbuvir. People who 
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didn't achieve SVR with teleprevir were found to have V36A/M, T54A/S, R155K/T, 
A156S/T and D168N mutations (139). 
 
8.4.4. Monitoring of viral response in the era of DAAs 
Only about 1 million of the estimated total 80 million people infected with hepatitis C 
virus have access to HCV treatment. With the use of DAAs for treatment of HCV 
infection, there is a possibility of cure. Within 3 months of treatment, 95% of patients 
attain cure, especially because of efficacy of drugs, increased compliance, ease of 
treatment and low cost. Continuous monitoring of HCV RNA levels is required to assess 
the response to therapy and to modify the drug regimen, if needed. 
 
9. Limitations for adequate management of hepatitis C virus infection 
Management of HCV infection involves estimation of HCV RNA and detection of the 
infecting HCV genotype. Initiation of therapy depends on pre-treatment viral load and 
HCV genotype. Duration of therapy and the current treatment strategies are influenced 
by HCV RNA quantification (viral load estimation) and HCV genotype (140). These 
assays are unfortunately available in very few laboratories in India, leaving low resource 
settings at a disadvantage in optimally managing HCV infected individuals (141).  
HCV quantification is most reliably done by freezing plasma/serum within 6-8 hours 
after blood draw. Detection of HCV RNA in resource-limited settings therefore is 
difficult due to the challenges of collection, storage and transport to larger reference 
laboratories.  Plasma/serum samples need to be centrifuged and separated within 6 hours 
of collection and frozen at -60°C until the time of testing. Shipment of plasma to larger 
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reference laboratories for these tests requires dry ice shipments, which is also logistically 
difficult. 
Thus, newer and simpler methods for collection and transport of sample from distant 
places to higher centres are required.  
 
10. Dried blood spots 
Dried blood spots (DBS) have recently been studied as an alternative specimen to 
plasma for detection of antibodies to HCV as well as for detection and quantification of 
HCV RNA (142). DBS has already been evaluated as a method of collection and storage 
of blood for HIV and HBV infections. It is a cost effective and easier method for 
collection of blood samples (143,144). Collection of DBS is a less cumbersome  and 
minimally invasive method requiring only a finger prick and spotting of whole blood 
onto filter paper cards (145). Thus, DBS collection in resource-limited settings and then 
its transportation at ambient temperature to the reference laboratories for HCV RNA 
estimation, is one of the means by which current HCV infection can be detected and 
followed-up, in remote areas (146). 
The idea of collecting blood on a paper card and subsequently using these dried blood 
spots (DBS) for diagnostic purposes originated a century ago, with Ivar Christian Bang 
using DBS eluates to determine blood glucose (147). Since then, DBS testing for 
decades focused on infectious diseases diagnosis (148) especially in low resource 
settings and for the inherited metabolic disorders screening in newborns (149). 
Recently, DBS has been used for a variety of tests and applications.  
The advantages of testing of DBS, as summarized by Chapman in 1924 are (150): 
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a. Lesser volume of blood, compared to conventional venipuncture method is 
required. 
b. It provides a cost-effective, minimally invasive and simple alternative for 
collection of blood for testing. 
c. There is minimal risk of haemolysis of blood or contamination by other micro-
organisms such as bacteria. 
d. Less deterioration of analytes overtime and easy storage and transport for 
prolonged durations. 
 
There has been an upsurge in the usage of DBS as a preferred method of collecting 
samples from remote areas because of its aforementioned advantages. In the past 
decade, it has been evaluated as a sample for testing of HIV, HBV and HCV infections 
(151,152). With the advent of DAAs for therapy of hepatitis C virus infection, 
monitoring of HCV RNA has gained even more importance for ascertaining response 
to therapy. 
 
 
Figure 9. Whatman 903 protein saver cards (commonly used for spotting blood) 
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10.1. Evaluation of DBS for virological studies 
To evaluate DBS as a method for sample collection, storage and transport to referral 
centres, many studies have been undertaken. 
In a study by Johannessen et al., in rural Tanzania, 98 plasma and DBS pairs were 
compared and HIV-1 RNA was detected in 100% of DBS samples when plasma viral 
loads were >3000 copies/ml (153). Another study in Burkina Faso, demonstrated the 
benefits of using DBS for the serological detection of HIV, HBV and HCV infections 
in settings where the laboratory facilities for their detection were non-existent (151). 
Marjorie Monleau et al., studied the effects of different storage conditions i.e. 20ᵒC & 
37ᵒC on DBS and came to the conclusion that viral monitoring is still feasible from 
DBS after storage for 3 months at 37ᵒC (154). A study done in Bangalore, by Neogi et 
al. studied the effects of various storage conditions on DBS and its effect on HIV viral 
load and came to the conclusion that DBS can be used as a collection and storage 
method of blood samples for viral load monitoring in HIV (155).  
Studies by Lee CE et al. (156), Ross RS et al. (143), Boa-Sorte et al. (157) and Mössner 
BK et al. (158) in various parts of the world have further emphasised that dried blood 
spots can be used as a means of sampling in remote areas where there are no facilities 
for viral testing. 
 
10.2. Evaluation of DBS for HCV testing 
Various studies have evaluated DBS as a specimen for HCV testing. In one of the 
earliest studies on DBS for HCV in 1997, anti-HCV antibodies were detected in all 168 
known positive samples spotted on Guthrie card filter papers (159).The findings were 
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correlated later in the study by McCarron B. et al. where  detection of anti-HCV in DBS 
samples showed to have very high sensitivity and specificity (160). In a study by Abe 
K. et al., serum samples were spotted onto filter papers and stored at room temperature 
for upto 4 weeks. PCR was done at the end of 1, 2, 3 and 4th week to check for stability 
of HCV RNA, which was detectable at the end of 4th week, though showed a reduction 
of almost 10 folds in amount (161). Solomone M. and colleagues in 2002, assessed the 
stability of HCV RNA in DBS for over a period of 11 months and the nucleic acid was 
preserved until the duration of the study (162).  
Studies conducted in the recent past by Tullion E et al. in 2010 (146) and Dokubo EK 
and colleagues in 2014 (142), concluded that DBS samples are sensitive and specific 
for HCV antibodies and HCV RNA and can be used as an alternative to plasma.  
Cloherty et al. concluded that DBS, being stable at room temperature and at 2-8ᵒC for 
upto 10 weeks can allow for storage and shipment and is an effective method for HCV 
screening (163). DBS has been shown to be stable at different conditions such as  22-
26ᵒC, 2-8ᵒC and -20ᵒC (164).  In a review, Greenman et al. have concluded that DBS 
has potential for use in HCV RNA detection, quantification and genotyping. DBS may 
be sufficient to detect and quantify HCV RNA for the purpose of HCV diagnosis. There 
was significant variation among viral load endpoint detection limits reviewed in the 
study. Lowest threshold of 150–250 IU/mL was found in highest-powered study 
designed specifically to measure endpoint sensitivity (165). 
 
The following table shows cumulative sensitivity and specificity of DBS for various 
parameters tested in HCV infection:  
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Tests Sensitivity Specificity References 
HCV RNA 65.9%-98.1% 100% (165–168) 
Anti-HCV 97.5%-100% 95.95%-100% (146,164,166,169) 
HCV core antigen 64.1% 100% (167) 
 
There are only a handful of studies from India evaluating the feasibility of DBS as a 
sample. Most studies have evaluated DBS for HIV detection and quantification, with 
high correlation between DBS and plasma values suggesting it can be used as a sample 
in suspected HIV cases (155,170–172). 
Nandagopal et al., in their study published in 2014, evaluated DBS samples for detection 
of anti-HCV and it was found to be 100% sensitive and specific (169). In a study by 
Lakshmi V. and colleagues, HCV was detected by loop mediated isothermal 
amplification (LAMP) from DBS samples with the resulting sensitivity and specificity 
of 100% (173). This further corroborates that DBS is comparable to plasma for 
qualitative detection of hepatitis C virus. 
 
11. Rationale for this study 
There are no studies evaluating the effect of the extreme temperature conditions of the 
Indian subcontinent on DBS for the detection of HCV RNA. Many studies from 
developed countries have studied the role of room temperature on DBS for estimating 
HCV viral loads. Room temperature in most parts of the developed world is mostly 
≤25ᵒC. However, there are no studies that have looked at storage at ambient 
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temperatures in this country, which is often ≥37ᵒC, especially between April to 
September of each year.  
Our study aims at filling the lacunae in the knowledge about the feasibility and 
effectiveness of DBS as a sample for collection, storage and transport of blood for HCV 
RNA quantification, HCV core antigen detection and HCV genotyping at variable 
temperatures (4ᵒC & ≥37ᵒC). The lower temperature of 4ᵒC is chosen because some 
laboratories may be able to store DBS samples at this temperature and also ship them at 
4ᵒC. Most laboratories will only be able to store and transport them at ambient 
temperature which is highly variable and often exceeding 37ᵒC, thus justifying the 
higher temperature of ≥37ᵒC. 
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MATERIALS AND METHODS 
1.1. Study Design 
This is an observational study to assess the diagnostic accuracy, in which hepatitis C 
infected, treatment naive patients who presented to the Department Of Clinical 
Virology, Christian Medical College, Vellore for HCV viral load quantification and 
genotyping were included. Dried blood spots from patients were collected, which were 
later eluted and quantified using Abbott Real Time HCV assay (for HCV RNA) and 
Abbott ARCHITECT HCV Ag assay (for HCV core antigen). This was then compared 
with the routine plasma based assays. 
Packed cell volume (PCV) values were estimated for each of the samples, to arrive at a 
correction factor/normalisation coefficient. This was to adjust for difference in sample 
volume and sample type between plasma and DBS samples. 
1.2. Ethics Approval 
This study was approved by Institutional Review Board, Christian Medical College and 
Hospital, Vellore (IRB Min No: 9687 (DIAGNO) dated 20.10.2015). 
1.3. Funding 
The study was funded by Internal Fluid Research Grant and Virology special fund. 
1.4. Study Duration 
This study was conducted over a period of 14 months (from March, 2016 to May, 2017). 
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1.5. Study Sample 
Samples from 40 consecutive treatment naive patients, with high index of suspicion of 
having hepatitis C virus infection; previous HCV RNA positive test results and HCV 
antibody levels ≥10 S/Co, referred from liver clinic were included in the study. This 
was over and above the required sample size calculated prior to starting the study. 
Written informed consent was obtained from the patients at the time of sample 
collection. 
1.5.1. Sample size calculation 
The required sample size to show that there was an agreement of about 0.8 (anticipated) 
in viral load between routine HCV RNA detection and whole blood spotted on to 2 
strips of Whatman 903 filter paper was found to be 36 patients with a power of 90% 
and at 5% level of significance. 
Agreement - Single Group - Continuous outcome-ICC (Testing against Population value) 
Sample reliability value  0.7 0.7 0.8 0.8 0.8 0.8 
Population reliability value  0.3 0.3 0.4 0.4 0.5 0.5 
Power (1- beta) % 80 90 80 90 80 90 
Alpha error (%) 5 5 5 5 5 5 
1 or 2 sided 2 2 2 2 2 2 
Number of replicates  2 2 2 2 2 2 
Required sample size  26 35 18 24 27 36 
 
 
 
45 
 
Formula for sample size calculation(174): 
 
 
1.5.2. Inclusion Criteria 
- Patients with hepatitis C virus infection 
- Patients more than 18 years of age 
- Treatment naive patients 
- Patients who give consent for the study 
 
1.5.3. Exclusion Criteria 
- HCV RNA negative plasma samples  
- Pregnancy 
- Patients less than 18 years of age 
- Patients not willing for consent 
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1.6. Data Sources 
Patient information such as age, sex, hospital no., address, AST, ALT, ALP, PT, APTT 
and haematocrit (PCV) values were collected from the online patient clinical records 
(Clinical Workstation). Samples were stored and tested in the Department of Clinical 
Virology. 
1.7. Study algorithm 
Algorithm followed for the study is as follows. 
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Study algorithm 
 
 
 
                                                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment naive patient comes to Department of Clinical Virology for routine 
molecular tests for HCV (detection/quantification/genotyping) 
Informed consent taken 
9ml of blood collected in EDTA tube 
2 ml of blood sample taken in 
K2EDTA tubes and sent to 
Department of Clinical 
Pathology for estimation of 
PCV, to arrive at a correction 
factor Approximately 7ml of 
whole blood to generate 
plasma for routine HCV 
RNA detection using 
reference standard (HCV 
RNA real-time PCR) 
Whole blood (50µl on each circle, 5 
spots on each strip) spotted onto two 
strips of Whatman 903 filter paper  
One strip with 
desiccant placed at 
4ᵒC for 15 days 
One strip placed at 
≥37ᵒC, with 
desiccant for 15 days Negative for 
HCV RNA 
Positive for 
HCV RNA 
Excluded 
from the 
study 
Stored at -20ᵒC until time of testing 
DBS samples of HCV RNA positive patients alone eluted 
Abbott m2000sp automated extraction system 
RNA extract 
Detection/quantification of 
HCV RNA 
Abbott m2000rt HCV Real 
time PCR 
HCV genotyping 
NS5B region based sequencing using ABI 
PRISM 310 Genetic Analyzer, for a 
proportion of patients  
HCV core antigen estimation  
Plasma and DBS samples by Abbott 
ARCHITECT HCV Ag assay 
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2.1. Processing of blood samples 
9 ml blood collected in sterile vacutainer tubes containing potassium ethylene diamine 
tetra acetic acid, after obtaining informed written consent. An additional 4 ml K2EDTA 
tube taken and 2ml blood collected in it for the purpose of estimating packed cell 
volume (PCV). Two Whatman 903 protein saver cards collected and labelled with 
unique study identification number, date of collection and the temperature (4ᵒC or 
≥37ᵒC), in which it will be kept.  
The whole blood was spotted onto two Whatman 903 protein saver cards. Each 
Whatman 903 card has 5 sample slots. 50 µl of whole blood spotted onto each of the 
sample slots in the two cards (Totally 500 µl spotted, on two cards). The cards were left 
to dry, at room temperature for 6 hours. Cards were then put into separate zip lock 
pouches with desiccant. Afterwards, card labelled as A (4ᵒC) was placed in a box and 
stored in refrigerator and card labelled as B (≥37ᵒC) was put in another box and kept in 
walk in incubator with temperature ≥37ᵒC, for 15 days duration. 
After 15 days, the cards were taken out of their respective boxes and kept at -20ᵒC, until 
the time of testing. 
3.1. Elution of DBS cards 
3.1.1. Materials required 
(i) Abbott mLysis Buffer 
(ii) 15ml Tarson tubes 
(iii) Puncher 
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(iv) Clean forceps 
(v) Sterile petri dishes 
(vi) Ethanol 
(vii) Calibrated pipettes: 10-1000µl with appropriate sterile tips 
3.1.2. Procedure 
HCV RNA elution was performed according to the protocol by David et al. (171)  
 Bio-safety hood cleaned with ethanol and ultraviolet light switched on for 15 
minutes. 
 DBS samples, mLysis buffer, 15 ml Tarsons tubes (labelled), puncher, sterile 
forceps, sterile petri dishes, pipettes and appropriate tips placed near the site. 
 1.7 ml of mLysis Buffer aliquoted into separate Tarsons tubes. 
 DBS cards selected, unique identification number and date of collection noted 
and matched with that of the Tarsons tube. 
 3 punches from one sample slot, punched out using the puncher. Two sample 
slots (6 punches) for each DBS strip. 
 The 6 punched out DBS samples put in the corresponding Tarsons tube and kept 
at room temperature for 2 hours with intermittent agitation. 
 After 2 hours, Tarsons tube with the DBS punches centrifuged at 4500rpm for 2 
minutes. 
 The eluate (750µl) used for RNA extraction. 
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3.2. HCV RNA Extraction 
This process is same for HCV DBS samples as well as for the plasma samples. Blood 
samples collected from the patients in 10 ml vacutainer tubes, after spotting onto 
Whatman 903 protein saver cards, was centrifuged at 2500 rpm for 10 minutes at 4ᵒC. 
Plasma was separated and added to 1.5 ml Tarsons vials, vortexed and stored at -60ᵒC 
until the time of testing. 
Principle: 
Abbott m2000sp nucleic acid extraction works on the principle of utilising magnetic 
microparticles for effective extraction. Lysis buffer lyses the virus and RNA is released, 
which attach to the magnetic microparticles and later wash buffer help in purification 
of the nucleic acid extract and the elution buffer finally elutes the nucleic acids. 
3.2.1. Materials required: 
(i) Abbott RealTime HCV Amplification Reagent Kit 
     - Abbott RealTime HCV Internal Control 
     - Abbott RealTime HCV Amplification Reagent Pack 
(ii) Abbott RealTime HCV Control Kit 
     - Abbott RealTime HCV Negative Control 
     - Abbott RealTime HCV Low Positive Control 
     - Abbott RealTime HCV High Positive Control 
(iii) Abbott m2000sp 
(iv) 200 ml reagent vessels 
(v) 5 ml reaction vessel 
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(vi) Sample racks 
(vii) Abbott 96- Deep well plate 
(viii) Abbott 96- Optical reaction plate 
(ix) Round bottom 12.5mm X 75 mm sample tubes 
(x) Master mix vial 
(xi) Abbott optical adhesive cover with applicator 
(xii) Calibrated pipettes 10 µl-1000µl, with corresponding pipette tips 
 
3.2.2. Assay Protocol 
I. Abbott m2000sp initialization 
a. Machine switched on and user log in done 
b. START button pressed and any other processes held back until the 
machine displays READY 
II. Daily maintenance 
a. Performed according to instruction on the computer 
b. Checked whether screws and syringes are tight  
c. Tubing checked for kinks/bends  
d. Tip holder of LiHA tightened 
e. Platform cleaned with 70% rectified spirit 
f. Extensive flush performed 
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III. Nucleic acid extraction 
PCR reagent preparation room 
 Plasma samples, eluted DBS samples (if refrigerated before), assay controls and 
internal controls are thawed at normal room temperature. All the samples vortexed 
for 2-3 seconds, to allow proper mixing of the sample. 
 Plasma samples further spinned down at 5000 rpm for 5 minutes at room 
temperature. 
 750 µl of plasma, DBS eluate added in the respective reaction vessel, already 
labelled with lab number/unique study identification number. 
 Negative Controls, low and high positive controls, internal quality control, plasma 
samples, DBS eluates placed into m2000sp sample rack. 
 Sample rack taken to the Abbott m2000sp work area. 
Abbott m2000sp Work Area 
 Abbott mSample preparation RNA bottles swirled to ensure proper mixing of 
reagents and poured into the appropriate reaction vessels as follows: 
a) Reagent carrier #1 location 1 - mLysis Buffer 
b) Reagent carrier #1 location 2 – Empty 
c) Reagent carrier #1 location 3 - mMicroparticles (Added just 
before starting the extraction) 
d) Reagent carrier #2 location 1 - mWash1 RNA 
e) Reagent carrier #2 location 2 - mWash2 RNA 
f) Reagent carrier #2 location 3 - elution buffer 
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 Carrier racks with the Abbott mSample preparation RNA reagents, Abbott 96-deep 
well plate and the sample rack loaded onto the Abbott m2000sp worktable. 
 5 ml Reaction vessels kept in the room temperature zone into the m2000sp 1ml 
subsystem carrier. 
 0.5 ml HCV RNA extraction procedure selected from run sample extraction screen. 
Calibrator number and lot number entered onto the screen.  
 Sample extraction protocol initiated. 
 
Master Mix Preparation 
A. Automated Master Mix Preparation 
- Amplification reagents thawed and the vials tapped at the bottom  
- Amplification vial caps removed and discarded 
- Amplification reagents, master mix vial and Abbott 96-well optical reaction 
plate loaded onto m2000sp worktable, after extraction procedure is complete. 
- Appropriate deep well plate selected from the run master mix addition screen, 
corresponding to the sample preparation and extraction. 
- Master mix addition protocol for Abbott m2000sp initiated. 
 
B. Manual Master Mix Preparation 
- This step performed if automated master mix preparation fails. 
- 375 µl of Reagent 1 and 917 µl of Reagent 2 added to Reagent 3. 
- Reagent 3 tube mixed well. 
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- 50 µl of contents of Reagent 3 tube transferred to the slots in the optical plate. 
- 50 µl of eluted RNA added to the corresponding slot from deep well plate to 
the optical plate. 
- Plate sealed and transferred to m2000rt. 
3.3. Nucleic acid Amplification 
Principle:  
5' UTR region of HCV genome is the target for the Abbott RealTime HCV assay, as 
this is a highly conserved and specific region for hepatitis C virus. During the 
amplification, thermostable rTth DNA polymerase converts the target RNA to cDNA 
because of its reverse transcriptase activity. During the denaturation step, the 
temperature rises above the melting point of cDNA:RNA and it dissociates. Second 
primer then anneals to the cDNA strand and rTth enzyme's DNA polymerase activity 
extends it to form a double stranded DNA. Repeated cycles of high and low 
temperatures results in an exponential increase in the target sequences. An internal 
control i.e. hydroxypyruvate reductase gene from Cucurbita pepo is also used to assess 
the adequate working of the assay. 
Probes which attach to the target sequences, if present, are also added to give a 
fluorescent signal which can be detected. 5' end of probe has a fluorescent moiety and 
a quencher is present at its 3' end. If there are no target sequences, the quencher remains 
in contact with the fluorophore and no signal is emitted. On presence of target sequence 
the probe hybridises to it which results in separation of fluorophore and quencher 
resulting in fluorescence which is detected. Stored calibration curves are used to 
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quantitate HCV RNA in samples and controls, which is reported automatically by the 
Abbott m2000rt. 
3.3.1. RNA amplification 
Amplification Room 
 UPS switched on and wait for indicator light to turn green. 
 Abbott m2000rt switched on and initialized. Leave it for 15 minutes to warm up. 
 Sealed Abbott 96-well optical reaction plate transferred to amplification room and 
placed in the initialized Abbott m2000rt. 
 Test order from m2000sp imported and run is set up. 
 Result saved and printed out from the computer after the run is over. 
 
Note: Master mix should be added within 60 minutes of completion of sample extraction 
and m2000rt protocol should be started within 60 minutes of completion of master mix 
addition protocol. 
 
4.1. HCV genotyping 
A representative region of HCV can be sequenced to ascertain the genotype. Simmonds 
et al., used NS5b region to categorise HCV into 6 different genotypes and this was used 
to genotype HCV in our study. In this process, RNA is converted into cDNA by reverse 
transcription and this cDNA is subsequently amplified. A hemi-nested PCR is run to 
genotype HCV where specific NS5b primer is used in the second round PCR.  
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Other methods such as PCR-RFLP of 5' non coding region and sequencing of HCV core 
region can also be employed for sequencing hepatitis C virus (175). 
4.1.1. Manual extraction of HCV RNA 
Stored extract of nucleic acid from the m2000sp step can be used or plasma/DBS eluates 
can be subjected to manual extraction, for a better yield of nucleic acids. 
The protocol for manual extraction of HCV RNA is as follows: 
4.1.2. Materials Required: 
(i) Plasma samples/DBS eluate (freshly prepared or stored) 
(ii) QIAamp® Viral RNA Mini kit 
- AVL Buffer 
- AW1 Buffer 
- AW2 Buffer 
- AVE Buffer 
- QIAamp Mini Spin Columns 
- Collection tubes (2 ml) 
(iii) Ethanol 
(iv) 1.5 ml Microcentrifuge tubes 
(v) Calibrated pipettes: 10-1000µl and 20-200µl with appropriate sterile tips. 
4.1.3. Procedure: 
RNA extraction was performed according to the manufacturer's instructions. 
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 Negative control and samples thawed to room temperature before starting the 
procedure. 
 Carrier RNA solution prepared by adding 310 µl of AVE Buffer (elution buffer). 
 AVL Buffer and carrier RNA-AVE buffer mixed in appropriate proportions, 
aliquoted and stored at 4-8ᵒC for later use. 
 Microcentrifuge tubes labelled appropriately. 
 560 µl of thawed and vortexed AVL buffer-carrier RNA solution added into each 
microcentrifuge tube. 
 140 µl of plasma/DBS eluate added to the respective tubes and pulse vortexed. 
 Tubes incubated at room temperature for 10 minutes and then centrifuged at 8000 
rpm for 1 min. 
 560 µl of Ethanol was added to each tube, pulse vortexed and then spun down at 
8000 rpm for 1 min. 
 630 µl of this sample transferred to spin column in a collection tube and 
centrifuged at 8000 rpm for 1 minute. 
 Filterate along with the collection tube discarded and spin column placed in a 
new collection tube. 
 Remaining 630 µl added in the spin column and centrifuged at 8000 rpm for 1 
minute. 
 Again the collection tube discarded and spin column placed in new collection 
tube. 
 500 µl of AW1 buffer added to the spin column in new collection tube and spun 
again at 8000 rpm for 1 minute. 
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 Collecting tube discarded and spin column placed in a new collecting tube. 
 500 µl of AW2 buffer added to the spin column and it was centrifuged at 14000 
rpm for 3 minutes and collecting tube discarded afterwards and spin column 
placed in new microcentrifuge tube. 
 60 µl of Elution buffer (AVE buffer) was added to the spin column. It was 
allowed to sit for 1 minute and then spun for 8000 rpm for 1 minute. 
 The spin column was discarded in the final step and the RNA extract in 
microcentrifuge collected. 
 
4.2.1. First Round PCR 
It was followed using reagents from Titanium® One-Step RT-PCR Kit (Clonetech 
Laboratories Inc., TaKaRa Bio Company, Japan).  
The primer sequences used were: 
Primer Nucleotide Sequence 
p1203 5' GGGTTCTCGTATGATACCCGCTGCTTTGACTC 3' 
p1204 5' GGAGGGGCGGAATACCTGGTCATAGCCTCCGTGAA 3' 
 
 
4.2.2. Master Mix Preparation 
Performed in clean room. The various reagents and reaction volumes used for a single 
reaction are as follows: 
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Reagents Volume for a single reaction (µl) 
10x One step Buffer 
50x dNTPs Mix 
Recombinant RNase inhibitor 
Thermo stabilizer 
GC melt 
Oligo dT primers 
50x Titanium Taq Polymerase 
p1203 (25 picomole/μl) 
p1204 (25 picomole/μl) 
 
5.0 µl 
1.0 µl 
0.5 µl 
25.0 µl 
10.0 µl 
1.0 µl 
1.0 µl 
0.5 µl 
0.5 µl 
 
                                     Total                                           45.3 µl                                      
Master mix was prepared in the clean room. To each master mix vial, 5 µl of RNA 
extract was added to make the final volume approximately 50 µl. 
Higher amount (10 µl of RNA extract) was added in case of samples having low viral 
loads or DBS samples. The final master mix tube, with the RNA sample added was then 
taken to the amplification room and put in Verti thermal cycler (Applied Biosystems, 
California, USA). 
The cycling conditions were as follows: 
50ᵒC for 60 minutes 
94ᵒC for 5 minutes 
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94ᵒC for 30 seconds 
65ᵒC for 30 seconds 
68ᵒC for 60 seconds 
68ᵒC for 2 minutes 
4ᵒC for   ∞           
                              
4.3.1. Gel Electrophoresis 
A gel electrophoresis using 2% agarose gel was run to check the amplification product. 
It was performed in PCR detection room. 
4.3.2. Materials required: 
(i) Agarose gel casting tray & Comb for sample slots 
(ii) Agar 
(iii) 100 ml 1XTAE buffer 
(iv) Ethidium bromide solution 
(v) Gelpilot loading dye 
(vi) 1000bp molecular ladder 
(vii) Electrophoresis tank 
(viii) Gel Doc 
(ix) Calibrated pipettes (1-20 µl, 20-200 µl) 
(x) Corresponding pipette tips 
4.3.3. Procedure: 
 The agarose gel casting tray & comb for sample slots arranged.  
40 Cycles 
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 2 gm of agar weighed and dissolved in 100 ml 1X TAE buffer, kept in a round 
bottomed flask by boiling in the microwave. 
 40 µl of ethidium bromide added to the solution after cooling and this mixture 
poured onto the agarose gel setting chamber. 
 Agarose gel was left to set for 15 minutes. 
 After 15 minutes, the gel comb removed and agarose gel placed in the 
electrophoresis chamber. 
 Electrophoresis tank filled with 1XTAE buffer working solution (980 ml of 
MiliQ water and 20 ml of 50X TAE buffer) and 40 µl of ethidium bromide added. 
 3 µl of Gelpilot loading dye and 7 µl of amplicon mixed and transferred in the 
respective well, along with controls and 7 µl of molecular ladder in the last well. 
 Gel run at 120 Volts for 35 minutes. 
 After completion of electrophoresis, gel visualized in gel documentation system 
(BioRad, California, USA). 
 Amplicon size was compared with known base pair size in the molecular ladder 
to ascertain whether the target has been amplified. 
 
4.4.1. HCV second round PCR 
After getting the desired band in the first round of PCR, second round is done. It is not 
required to move ahead with second round of PCR, if there are no bands seen after the 
first round PCR and gel electrophoresis, as was the case in this study. 
Primers and primer sequences used in this reaction are given below: 
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Primer Nucleotide Sequence 
NS5b 5' TGATACCCGCTGCTTTGACTCNACNGTCAC 3' 
p1204 5' GGAGGGGCGGAATACCTGGTCATAGCCTCCGTGAA 3' 
 
 
Master mix preparation is performed in the PCR reagent preparation room.  The 
reagents and primers used for the second round PCR are: 
Reagents Volume for a single reaction (µl) 
10x PCR Buffer                             
dNTPs 
p1204 (50 pmol/µl) 
NS5B primer (50 pmol/µl) 
Taq polymerase 
Nuclease free water 
5.0 
0.4 
0.4 
0.4 
0.2 
38.6 
                             Total                         =                          45.0 
 
 
45 µl of prepared master mix transferred to separate vial and 5 µl of amplified product 
from the first round PCR added in the sample addition area to make the final volume 
50 µl. The vials are then subjected to second round PCR in thermal cycler in the 
amplification room, with following cycling conditions: 
94ᵒC for 3 minutes 
63 
 
94ᵒC for 30 seconds 
54ᵒC for 40 seconds 
72ᵒC for 20 seconds 
72ᵒC for 3 minutes 
 
4.5. Amplified product detection 
Amplified product was then subjected to gel electrophoresis, as described earlier and 
gel image taken. 
4.6.Pre-cycle sequencing clean up 
 Sterile MilliQ water added to amplification product obtained in round two PCR, 
to make the final volume 100 µl. 
 Contents transferred onto its respective labelled well in millipore plate. 
 Millipore plate connected to vacuum pump. 
 Negative pressure applied until the well is completely dry. 
 100 µl of sterile MilliQ water added again and previous steps repeated. 
 20 µl of sterile MilliQ water added and plate kept on shaker for 2 minutes at 7000 
rpm. 
 The contents aspirated and added into fresh PCR tubes. 
 
4.7.1. Sequencing PCR  
Master mix preparation for Sequencing PCR 
 Master mix preparation requires following reagents and is done in PCR reagent 
preparation room.  
40 cycles 
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Reagents Volume for a single reaction (µl) 
RR (Ready Reaction) mix 
RR buffer 
p1204 (1 pmol/µl)/NS5B primer (1 
pmol/µl) 
Nuclease free water 
0.5 
1.75 
2.0 
                                                          
4.75 
                               Total                       =                          9 µl 
 9 µl of master mix added to each PCR tube (one tube with p1204 primer and 
other with NS5b primer). 
 1 µl of amplified and pre-clean up product added to the respective tubes to make 
the final volume 10 µl. 
 The PCR tubes placed in thermal cycler in the amplification room, with cycling 
conditions shown below: 
96ᵒC for 15 seconds 
50ᵒC for 20 seconds 
60ᵒC for 4 minutes 
15ᵒC for ∞ 
 
4.8. Post-Cycle Sequencing Clean Up 
 30 µl of injection solution added to the sequencing PCR amplified solution to 
make the final volume 40 µl. 
 All 40 µl transferred to the respective well in the post-sequencing PCR millipore 
plate. 
25 cycles 
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 Vacuum pump connected and negative pressure applied until the wells are 
completely dry. 
 Previous two steps repeated again. 
 30 µl of injection solution added and kept in a shaker at 7000 rpm for 2 minutes. 
 Contents aspirated in the genetic analyser tube and covered with a septa. 
 
4.9. Sequencing and BLAST 
 The samples need to be loaded in ABI PRISM 310 genetic analyser (Applied 
Biosystems, California, USA). 
 Electropherogram obtained from each sample and Bioedit software used to align 
both forward and reverse nucleotide sequences and get a complete nucleotide 
sequence. 
 The sequence is then uploaded on HCV BLAST (http://hcv.lanl.gov) and 
genotype ascertained based on the homology. 
 
5.1. HCV genotyping by Abbott Real Time HCV Genotype II Assay 
Principle: 
Abbott Real Time HCV Genotype II assay is a reverse transcriptase PCR assay, which 
is used to identify the HCV genotypes 1, 1a, 1b, 2-5 by use of different primers and 
probes specific for each genotype. The four sets of primers target 5' UTR region of all 
HCV isolates, NS5b region of genotype 1a, NS5b region of genotype 1b and the 
66 
 
hydroxypyruvate gene of the internal control, respectively. In this assay, one sample is 
subjected to three different reactions (A, B & C) involving different probes and 
fluorescent dyes for the detection of different genotypes. The different reactions and the 
respective probes and dyes are given below: 
Reaction Probe Fluorescent Dye 
A All HCV isolates 
Genotype 1a 
Genotype 3 
FAM 
VIC 
NED 
B Genotype 1 
Genotype 1b 
Genotype 2 
NED 
VIC 
FAM 
C Genotype 4 
Genotype 5 
VIC 
FAM 
 
In addition, there is a passive reference dye ROX and Quasar 670 for the internal 
control. 
5.2. Abbott RNA Manual Extraction for Real Time Genotype II assay 
5.2.1. Materials required: 
(i) Temperature controlled dry heating blocks (50ᵒC & 75ᵒC) 
(ii) Magnetic racks 
(iii) 12X75 mm reaction vessels 
(iv) 1.5 ml microcentrifuge tubes 
(v) mLysis buffer 
(vi) Magnetic mMicroparticles 
(vii) mWash1 buffer 
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(viii) mWash2 buffer 
(ix) mElution buffer 
(x) 96 well polypropylene plate 
(xi) Plasma sample/DBS eluate 
(xii) Calibrated pipettes (20-200 µl and 100-1000 µl) and corresponding pipette tips 
 
5.2.2. Procedure 
Sample preparation area 
 667 ml of internal control mixed with 23.33 ml of mLysis buffer (for 8 extraction 
reactions). 
 mLysis bottle mixed by gentle inversion for 5-10 minutes and mMicroparticles 
resuspended by swirling action. 
 12x75 mm labelled reaction vessels placed on a non magnetic rack and 100 µl of 
mMicroparticles, 2.4 ml of mLysis buffer and 500 µl of respective sample added 
to each vessel. 
 Reaction vessels placed at 50ᵒC heating block after mixing the samples, for 20 
minutes. 
 After 20 minutes, reaction vessels placed on magnetic rack for 2 minutes. 
 Lysate in the reaction vessels discarded leaving microparticles at one side. 
 Reaction vessels transferred to non-magnetic rack and 700 µl of mWash1 buffer 
added to each vessel and mixed, to resuspend the microparticles. 
 Contents transferred to 1.5 ml microcentrifuge tube and placed on magnetic rack 
for one minute, during this time the mWash1 buffer removed, leaving the 
microparticles undisturbed on one side. 
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 After 1 minute, tubes transferred to non-magnetic rack and the previous step 
repeated. 
 After second wash with mWash1, 700 µl of mWash2 buffer added and 
microparticles resuspended in the solution. It is again placed on magnetic rack, 
mWash2 discarded and the step repeated to complete 2 washes with mWash2. 
 25 µl of mElution buffer added to the microcentrifuge tubes and magnetic 
microparticles resuspended in the solution by gentle aspiration and dispense 
procedure. 
 The tubes are then placed onto 75ᵒC heating block and incubated for 20 minutes 
and then transferred to non-magnetic rack. 
 63 µl of mWash2 added to each tube and it is then placed on the magnetic rack 
for the microparticles to attach to the magnetic side, leaving behind the eluate. 
 Eluted samples with the RNA removed and aliquoted into fresh eppendorf tubes. 
 
5.3. Master mix preparation and amplification 
5.3.1. Materials required: 
(i) Abbott RealTime HCV Genotype II Amplification Reagent Kit  
a) Abbott RealTime HCV Genotype II Internal Control 
b) Abbott RealTime HCV Genotype II Amplification reagent packs A, B & 
C 
c) Abbott RealTime HCV Genotype II Control kit (with positive and 
negative control) 
(ii) RNA extracted manually from plasma/DBS eluate samples 
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(iii) Abbott m2000sp instrument 
(iv) Abbott m2000rt instrument 
(v) Abbott 96-well optical reaction plate 
(vi) Abbott 96-well deep well plate 
(vii) Optical adhesive cover & cover applicator 
(viii) Microcentrifuge tubes 
(ix) 20-1000 µl calibrated pipettes with corresponding aerosol barrier tips 
 
5.3.2. Master mix preparation 
 Abbott RealTime HCV Genotype II Amplification Reagent Kit and RNA 
extracts thawed at room temperature. 
 Contents of HCV Genotype II Amplification kit mixed by inverting 5-10 times. 
 Amplification reagent packs A, B & C each have 3 reagent containers having 
activator (activation reagent), primer & probe mix and Taq enzyme 
(oligonucleotide reagent), respectively. 
 83.67 µl of activator and 246 µl of primer & probe mix were added to bottle 
containing solution of thermostable rTth polymerase enzyme, for each reagent 
pack and mixed by inverting 5-10 times. 
 40 µl of master mix added onto labelled 96-well optical reaction plate, such as 
each sample has 3 slots (for Reagent A, B & C). 
Sample Preparation area 
 96-well optical reaction plate containing the master mix transferred to the sample 
preparation area and 20 µl of RNA extract added in the respective wells. 
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Amplification room 
 Abbott m2000rt switched on, initialised and allowed to warm up. 
 96-well optical reaction plate with added master mix and extracted RNA loaded 
into the system. 
 Abbott RealTime HCV Genotype II protocol selected and allowed to run. 
 Results collected after 2 hours 45 minutes. 
 
6.1. HCV Core Antigen Estimation by Abbott ARCHITECT HCV Ag Assay 
Principle: 
Abbott ARCHITECT HCV Ag Assay is an automated chemiluminescent microparticle 
immunoassay, which detects the nucleocapsid peptide 22 released from hepatitis C virus 
during replication. In this method, anti-HCV is coated onto the microparticles and if the 
sample contains HCV core antigen, on addition it binds to the anti-HCV. Acridinium 
labelled anti-HCV is added next after washing and then the pre-trigger and trigger 
solution is incorporated in the solution which gives a chemiluminescent reaction, 
measured in relative light units (RLU). 
There is a direct correlation between the RLUs and amount of HCV core antigen in the 
sample. Previously generated ARCHITECT HCV Ag calibration curve is used to 
quantify HCV Core antigen. 
6.2. Materials required: 
(i) Abbott ARCHITECT i2000SR system 
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(ii) 6L47-11 ARCHITECT HCV Ag controls 
(iii) ARCHITECT i Pre Trigger Solution: 1.32% (w/v) Hydrogen Peroxide 
(iv) ARCHITECT i Trigger solution: 0.35 N Sodium Hydroxide 
(v) ARCHITECT i Wash Buffer: Phosphate buffer saline 
(vi) ARCHITECT i Reaction vessels 
(vii) ARCHITECT i Sample cups 
(viii) ARCHITECT i Septum 
(ix) ARCHITECT i Replacement caps 
(x) ARCHITECT HCV Ag Reagent Kit 
a) Microparticles (Murine anti-HCV coated) 
b) Conjugate 
c) Assay specific diluent 
d) Pre-treatment Reagent 1 
e) Pre-treatment Reagent 2 
f) Specimen diluent 
 
6.3. Assay Procedure: 
 Plasma/DBS eluate samples and reagents thawed at room temperature. 
 Samples vortexed to ensure proper mixing. 
 Reagent bottles inverted and swirled to ensure mixing and it should be checked 
that microparticles are resuspended in the solution. 
 ARCHITECT i2000SR initialized and daily maintenance performed. 
 It is ensured that ARCHITECT i reaction vessels are in adequate number. 
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 ARCHITECT HCV Ag reagent kit with septums loaded onto the system. 
 200 µl of plasma /DBS eluate samples added to sample cups and the sample 
carrier tray loaded into the system after entering the sample identification 
numbers, carrier tray number and position in the computer. 
 ARCHITECT HCV Ag assay selected in the computer and run is initiated. 
 Print out of results taken after completion of run in 40 minutes. 
 
7. Statistical Analysis 
The descriptive measures were presented as mean or median with standard deviations 
or Inter quartile range for all continuous variables like “viral load” whereas, frequencies 
and percentages were used for the categorical variables.  The agreement between routine 
plasma based PCR and whole blood on Whatman filter paper was presented using 
Interclass correlation (ICC). Bland Altman Plot was used to compare the agreement 
between the two methods. All data generated in the study were analyzed using 
Microsoft Excel and SPSS software. 
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RESULTS 
 
1. Baseline characteristics 
1.1. Gender wise distribution 
A total of 40 samples were included in the study. Out of the 40 patients, 27 (67.5%) 
were male and 13 (32.5%) female.  
 
Figure 10. Gender wise distribution of study patients 
 
1.2. Demographic profile of study patients 
Out of 40 patients, 14 (35%) were from Bangladesh, forming the largest ethnic group 
of the study population. Patients from West Bengal (8, 20%) formed the next larger 
group. They were followed by patients from Tamil Nadu (5, 12.5%) and Andhra 
Pradesh (4, 10%). 
67.50%
32.50%
Gender distribution
Males
Females
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The rest of the study population constituted patients from Jharkhand, Bihar, Madhya 
Pradesh, Sikkim, Assam and Mizoram.  
Table 1: Demographic profile of study patients 
Region Number of cases Percentage (%) 
Bangladesh 14 35 
West Bengal 8 20 
Tamil Nadu 5 12.5 
Andhra Pradesh 4 10 
Jharkhand 3 7.5 
Bihar 2 5 
Madhya Pradesh 1 2.5 
Assam 1 2.5 
Sikkim 1 2.5 
Mizoram 1 2.5 
Total 40 100 
 
 
1.3. Age distribution of study patients 
Only individuals ≥18 years were recruited in our study. The youngest patient enrolled 
in our study was 19 years old while the oldest was 83 years old. 
The median age of patients in our study was 51 (interquartile range: 63.5-42.5) years. 
Table showing the age distribution of patients is given below. 
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Table 2: Age wise distribution of study patients (n=40) 
 
 
 
1.4. Liver Function Test (LFT) profile of patients 
HCV infection leads to chronic liver disease. Condition of liver can be assessed by 
performing liver function tests. LFT parameters of the patients were as follows: 
 
a) Liver enzymes 
The median aspartate aminotransaminase (AST) level was 47.5 IU/L (interquartile 
range: 88.75-31.75). Median alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP) values were 54.5 IU/L (interquartile range: 77-26.5) and 81 IU/L (interquartile 
range: 114.5-67.5), respectively.   
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b) Coagulation profile 
It was assessed by checking the Prothrombin Time (PT) and Activated Partial 
Prothrombin Time (APTT). PT values were available for 34 patients, with the median 
being 11.25 seconds. APTT had a median of 37.4 seconds (for 25 patients). 
The variation in the liver enzymes for each patient is represented as follows: 
 
Figure 11. Liver enzyme values of study patients 
 
2. HCV RNA detection/quantification 
The mean plasma HCV RNA values and mean plasma HCV RNA log10 values for 40 
study patients were 1659218 IU/mL and 5.52 log10 IU/mL, respectively. Median plasma 
HCV RNA was 475657 IU/mL (interquartile range: 2095924-108221) and median log10 
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plasma HCV RNA value was found to be 5.67 (interquartile range: 6.32-5.03) log10 
IU/mL.  
A total of thirty six samples were included in the final statistical analysis, as HCV RNA 
values were available for all three subsets i.e. plasma, DBS at 4⁰C and DBS at ≥37⁰C 
for 36 of study patients. This was done for a better correlation analysis and to minimise 
any statistical error. 
a) Comparison of plasma HCV RNA and DBS HCV RNA kept at 4ᵒC 
DBS 4ᵒC HCV RNA values were available for 36 of study patients. One sample had 
the corresponding plasma HCV RNA value as 542 IU/mL or 2.73 log10 IU/ml and even 
though the DBS sample (A) was detected in the real time PCR, the result was expressed 
as <12 IU/mL of RNA. Three other samples gave errors on repeated runs and were not 
included in the final analysis. The corresponding viral loads of these three samples were, 
1.23 log10 IU/ml, 6.75 log10 IU/mL and 5.12 log10 IU/mL, respectively.  
Median HCV RNA values of DBS samples kept at 4ᵒC was 5708 (interquartile range: 
15127.50-1279) IU/ml. Corresponding median log10 HCV RNA value was 3.75 
(interquartile range: 4.17-3.10) log10 IU/mL. 
The difference in plasma HCV RNA log10 value and DBS (4ᵒC) HCV RNA log10 value 
is 1.92 logs. 
Plasma HCV RNA values and DBS (4ᵒC) HCV RNA values showed a high level of 
agreement with Pearson’s correlation coefficient of 0.950, as is shown in figure 14. 
Bland-Altman plot showed a high agreement between plasma HCV RNA values and 
DBS (4⁰C) HCV RNA values, as depicted in figure 13. 
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Figure 12. Scatter plot showing correlation between plasma (X-axis) & DBS 
(4ᵒC) (Y-axis) log10 HCV RNA values 
 
 
 
Figure 13. Bland-Altman plot showing correlation between plasma log10 HCV 
RNA & DBS (4ᵒC) log10 HCV RNA values 
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Correlation analysis showed a significant correlation R value was 0.950 (95% 
confidence interval: 0.903-0.974) and p<0.0001. 
 
Figure 14. Correlation between DBS log10 HCV RNA (4ᵒC) (X-axis) and plasma 
log10 HCV RNA (Y-axis), showing high correlation 
 
b) Comparison of plasma HCV RNA and DBS HCV RNA kept at ≥37ᵒC 
HCV RNA values were available for 38 of DBS samples kept at ≥37ᵒC. HCV RNA 
could not be quantified in two of the samples, since they yielded error codes repeatedly.  
The corresponding plasma viral load values of these two samples were 1.23 log10 IU/mL 
and 6.75 log10 IU/ml, respectively. 
Median HCV RNA value for DBS samples kept at ≥37ᵒC was 9800 (interquartile range: 
20169-1625) IU/ml. Median log10 HCV RNA value for such samples was 3.99 
(interquartile range: 4.30-3.21) log10 IU/mL. 
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The difference between the median plasma log10 HCV RNA values (5.67 log10 IU/mL) 
and median log10 HCV RNA value for DBS samples at ≥37ᵒC (3.99 log10 IU/mL) was 
1.68 logs. 
Log values of HCV RNA of DBS kept at ≥37ᵒC and plasma log values of HCV RNA 
showed high correlation with the correlation value of 0.943, as shown in figures 15 and 
17. 
 
 
Figure 15. Scatter plot showing correlation between plasma HCV RNA log10 
value (Y-axis) and log10 value of HCV RNA of DBS at ≥37ᵒC (X-axis) 
  
Bland-Altman plot analysing HCV RNA values of plasma and DBS at ≥37⁰C showed 
a high agreement, as depicted in figure 16. 
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Figure 16. Bland-Altman plot showing correlation between HCV RNA log10 
values of plasma and respective DBS ≥37ᵒC samples 
Figure 17 shows correlation analysis between log10 HCV RNA values of DBS at ≥37ᵒC 
and plasma log10 HCV RNA values showed a R value of 0.943 (95% confidence 
interval:0.892-0.971) and p<0.0001. 
 
Figure 17. Correlation between DBS (≥37ᵒC) log10 (X-axis) HCV RNA and 
plasma log10 HCV RNA (Y-axis) 
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c) Comparison of log values of HCV RNA of DBS sample at 4ᵒC and DBS sample 
at ≥37ᵒC 
Good correlation (0.974) was found between HCV RNA log10 values of DBS samples 
kept at 4ᵒC and the ones kept at ≥37ᵒC, as shown in figure 20. 
The median log10 HCV RNA value of DBS samples at 4ᵒC was 3.75 (interquartile 
range: 4.17-3.10) log10 IU/mL, while of DBS kept at ≥37ᵒC was 3.99 (interquartile 
range: 4.30-3.21) log10 IU/mL. This suggests that no deterioration of HCV RNA 
occurred at high temperature conditions (≥37⁰C) prevalent in the Indian subcontinent, 
especially during the summer. 
 
Figure 18. Scatter plot showing correlation between log10 HCV RNA values of 
DBS at 4ᵒC (X-axis) and at ≥37ᵒC (Y-axis) 
 
High agreement between HCV RNA value of DBS samples at 4⁰C and DBS samples 
at ≥37⁰C was shown by Bland-Altman plot in figure 19. 
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Figure 19. Bland-Altman plot correlating log10 HCV RNA values of DBS at 
≥37ᵒC and at 4ᵒC 
 
R value of 0.974 (95% confidence interval: 0.950-0.987) and p<0.0001 was found 
after performing correlation analysis, as is given below. 
 
Figure 20. Correlation between DBS log10 HCV RNA at ≥37ᵒC (Y-axis) and DBS 
log10 HCV RNA at 4ᵒC (X-axis) 
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3. Calculation of haematocrit corrected viral load 
Whole blood was spotted on the Whatman 903 filter paper and only 100 µl was eluted 
and run through Abbott m2000rt, while in case of routine samples 500 µl of plasma is 
used for the same assay. This resulted in need of a multiplication factor to adjust for 
sample volume and sample type difference between DBS samples and plasma samples 
(171,176). A correction factor/normalisation coefficient was calculated. 
Median haematocrit (PCV) value for 40 patients included in the study was 37.4% 
(interquartile range: 41.05-30.1). In DBS, the input volume was 100 µl. Substracting 
the median PCV value from hundred will give the amount of plasma in the DBS (100-
37.4= 62.6%). The correction factor for ascertaining plasma viral load in 100 µl was 
calculated as, 100/62.6 = 1.6.  
Moreover, in routine testing 500 µl of plasma is used but in DBS testing 100 µl of whole 
blood is spotted and eluted for estimation of HCV RNA. The correction factor for 
volume of sample was 500/100= 5.  
The final Normalisation/Correction factor taking into consideration both the volume 
and sample type was 8 (5 X 1.6).  
The normalised median log10 HCV RNA for DBS at 4ᵒC was 4.66 (interquartile range: 
5.09-3.98) log10 IU/mL and median log10 HCV RNA for DBS at ≥37ᵒC was 4.92 
(interquartile range: 5.12-4.14) log10 IU/mL.  
The difference between median plasma log10 HCV RNA i.e. 5.67 (interquartile range: 
6.32-5.03) and median log10 HCV RNA of DBS at 4ᵒC and DBS at ≥37ᵒC was 1.01 and 
0.75 logs, respectively. 
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4. HCV core antigen  
A total of 34 plasma samples and 29 DBS samples were subjected for HCV core antigen 
estimation.  
Median core antigen value for 34 plasma samples was 471 (interquartile range: 2987.58-
60.25) fmol/L. For 29 of these samples, which had corresponding DBS core antigen 
testing done the median core antigen was 325.35 fmol/L. 
Median HCV core antigen values for DBS samples kept at 4ᵒC and DBS samples kept 
at ≥37ᵒC were found to be, 4.64 (interquartile range: 5.63-3.73) fmol/L and 4.77 
(interquartile range: 6.14-3.77) fmol/L, respectively. 
a) Comparison of HCV core antigen values of plasma and DBS samples at 4ᵒC 
A total of 28 samples for which plasma and DBS (4ᵒC) core antigen values were 
available, were assessed for correlation. No significant correlation (0.031) was found 
between core antigen values of plasma and DBS samples kept at 4ᵒC, as shown below. 
 
Figure 21. Correlation between HCV core antigen values of plasma (X-axis) and 
DBS samples kept at 4ᵒC (Y-axis)  
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b) Comparison of HCV core antigen values of plasma and DBS samples at ≥37ᵒc 
Correlation was assessed for a total of 28 samples for which both the plasma and DBS 
at ≥37ᵒC core antigen values were available.  
A poor correlation (0.164, 95% Confidence interval: -0.22-0.506) was found between 
core antigen values of plasma and DBS kept at ≥37ᵒC, as given in figure 22. 
 
Figure 22. Scatter plot showing correlation between plasma (X-axis) and DBS 
kept at ≥37ᵒC (Y-axis) core antigen values 
 
c) HCV core antigen value comparison of DBS kept at 4ᵒC and DBS kept at 
≥37ᵒC 
HCV core antigen values of DBS kept at two different temperatures (4ᵒC & ≥37ᵒC) of 
29 patients were compared to ascertain the effect of temperature on HCV core antigen. 
A correlation of 0.730 (95% confidence interval: 0.496-0.865) was found between the 
two (refer figure 23). 
Figure 24 depicts good agreement between the HCV core antigen values of DBS 
samples kept at 4⁰C and DBS samples kept at ≥37⁰C in the Bland-Altman plot.  
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Figure 23. Correlation between HCV core antigen values of DBS at 4ᵒC (X-axis) 
and DBS at ≥37ᵒC (Y-axis) 
 
 
Figure 24. Bland-Altman plot showing correlation of HCV core antigen values of 
DBS at ≥37ᵒC and DBS at 4ᵒC 
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4. Plasma HCV RNA and plasma HCV core antigen comparison 
Plasma HCV core antigen values were available for 34 plasma samples. These values 
were compared with plasma HCV RNA log10 values of corresponding samples.  
Median plasma HCV RNA log10 value for the 34 samples taken into consideration was 
5.73 (interquartile range: 6.23-4.99) log10 IU/ml and median plasma log10 HCV core 
antigen values for the same plasma samples was 2.70 (interquartile range: 3.48-1.89) 
log10 fmol/L. 
 
The scatter plot showing correlation i.e. r=0.777 (95% confidence interval: 0.591-
0.884), p<0.0001, between the two is as follows: 
 
Figure 25. Scatter plot showing correlation between plasma HCV RNA (X-axis) 
and plasma HCV core antigen (Y-axis) values 
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5. HCV genotyping 
Out of 40 plasma samples, 35 were genotyped. Using plasma, 4 samples had low viral 
load and couldn't be genotyped. Genotyping was not asked for one sample. 
 
The frequency of various genotypes encountered in our study was: 
Genotype No. of patients 
Genotype 1 8 
Genotype 3 26 
Genotype 4 1 
 
 
 
Figure 26. Pie chart showing HCV genotypes among the study patients 
 
 
 
23%
74%
3%
HCV genotypes among study patients
Genotype 1
Genotype 3
Genotype 4
90 
 
a) Genotyping of DBS samples by the in-house assay 
A total of 9 paired DBS samples (at 4ᵒC and at ≥37ᵒC) with higher viral loads (range: 
4.93-4.04 log10 IU/mL) were selected and genotyping was attempted using the Sanger 
sequencing method. Automated RNA extraction was tried on all the 9 paired samples. 
A subset of samples which could not be amplified after automated extraction and 1st 
round PCR were again subjected to manual RNA extraction since the RNA yield is 
better with manual extraction procedure. None of the samples could be genotyped by 
the in-house assay employing both, automated as well as manual RNA extraction. 
 
 
Figure 27. Gel picture after 1st round (no bands for samples) 
 
b) Genotyping by Abbott Real Time HCV Genotype II assay 
Two DBS samples were subjected to Abbott Real Time HCV Genotype II assay. 
Genotype 1b was picked up for a DBS sample, both at 4ᵒC (viral load: 4.05 log10 IU/mL) 
& ≥37ᵒC (viral load: 4.04 log10 IU/mL). Another DBS sample was genotyped as 
genotype 3, both at 4ᵒC (viral load: 4.84 log10 IU/mL) & ≥37ᵒC (viral load: 4.93 log10 
IU/mL). This was in correlation with the genotyping result of the corresponding plasma 
sample. 
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Figure 28. Real time curve showing genotype 1b for a DBS sample  
                                                                                           
 
 
Figure 29. Real time curve showing Genotype 3 for a DBS sample  
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DISCUSSION 
 
Hepatitis C virus has a prevalence of about 1-2.5% worldwide (4) with about 6-11 
million people living with HCV in India (6). There are 7 known genotypes of HCV 
(68); genotype 3 and 1 are the most predominant in India (9).Transmission of HCV is 
mainly by percutaneous exposure to blood, perinatal and sexual routes (177).   
HCV infection is often asymptomatic with many people being unaware of having the 
disease. Spontaneous resolution seen in about 15-25% of population after an acute phase 
of illness (78). Liver cirrhosis and hepatocellular carcinoma are the major complications 
of chronic HCV infection. 
Diagnostic modalities available for HCV can be broadly classified as rapid tests, 
serological tests and molecular tests. Rapid tests and serological tests (ELISA and 
CMIA) detect antibody to hepatitis C virus (15). Recently, HCV core antigen estimation 
has also been used as a marker of hepatitis C infection. Positivity of HCV core antigen 
during the pre-seroconversion window period prior to seroconversion makes it a better 
predictor of acute infection. It can also be used to diagnose HCV infection in neonates 
and in immunosuppressed individuals (17). 
Molecular tests detecting HCV RNA are the gold standard which confirm current HCV 
infection and can detect even low titres (12-50 IU/mL) of HCV RNA in the plasma (16). 
It can be detected early in the course of infection and remain positive until the infection 
is cleared (99). 
Genotyping of HCV is currently required before starting the treatment. The duration 
and treatment regimen varies with the HCV genotype infecting the patient. With 
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genotype 3 or previously treated patients, the duration of treatment may be prolonged. 
The relevance of duration of therapy has declined with the use of DAAs (107,109).  
Patient care encompasses timely diagnosis of the disease, screening and monitoring the 
patients through the course of therapy to monitor the treatment response. HCV RNA 
quantification is considered the best method to assess therapy as antibodies to hepatitis 
C virus remain positive even in individuals who have spontaneously cleared the virus 
(178). HCV RNA is also superior to antibody detection in immunosuppressed patients 
and in individuals with high risk lifestyles and in those who are multi-transfused, as 
they have high chances of getting re-infected. 
HCV RNA detection, HCV genotyping are some tests which are available only in few 
specialised centres in a country such as India. For want of better diagnosis and 
monitoring, samples from distant resource-limited settings are sent to higher centres for 
HCV RNA quantification and genotyping of HCV, as treatment differs with different 
genotypes (69).  
Dried blood spots (DBS) have been used in the recent past as a means of easy sampling 
of patients, for convenient storage and transport of samples from distant resource-
limited settings to referral laboratories for testing of HCV (142). Effect of storage 
conditions, ambient room temperature and duration of storage on HCV RNA in DBS 
has also been evaluated in different studies.  
An earlier study evaluating stability of HCV RNA in DBS by Abe and Konomi showed 
that HCV RNA remained stable at room temperature for 4 weeks but there was a 10 
fold decline in the viral load over the period (161). Solomone et al., assessed HCV RNA 
from a set of DBS samples stored at room temperature for 11 months and found that the 
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positivity of the samples was preserved throughout the study (162).  Tuaillon et al. in 
their study published in 2009 found dramatic decrease in HCV RNA in DBS samples 
kept at room temperature for 6 days, while DBS kept at -20ᵒC showed no significant 
decline (146). HCV RNA was found to be stable at different temperatures for a period 
of one year in the study by Bennett et al. (179). In the study published in 2013, Brandão 
CPU et al, showed DBS to be stable at different conditions such as  22-26ᵒC, 2-8ᵒC and 
-20ᵒC for a period of 60 days (164). Gavin Cloherty and colleagues in their study found 
the HCV RNA to be stable in DBS for a period of 10 weeks at ambient room 
temperature and at 2-8ᵒC (163). No substantial difference was observed in HCV RNA 
DBS samples stored at 24ᵒC and at -80ᵒC over a period of 19 months in a study by 
Soulier et al. (167). 
Majority of the studies have evaluated the effect of ambient room temperature on DBS 
in temperate climates and did not assess the effect of tropical temperatures on stability 
of HCV RNA. There is limited data on effect of temperatures prevalent in Indian 
subcontinent on the integrity of nucleic acid of HCV, with only Nandgopal et al. and 
Lakshmi et al. studying the use of DBS in HCV diagnosis (169,173).  
In our study, whole blood from each study participant was spotted onto two Whatman 
903 protein saver cards. One card was stored at 4ᵒC for 15 days and other was incubated 
at ≥37ᵒC for 15 days, after drying. This was meant to simulate transport conditions from 
distant sites in the tropical climate widely present in India. These cards were then stored 
at -20ᵒC until the time testing. Plasma from the same patient was subjected to the routine 
viral load testing and genotyping. HCV RNA quantification, HCV genotyping and HCV 
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core antigen estimation of DBS was undertaken to evaluate feasibility of DBS as a 
specimen, by comparing DBS results with the corresponding plasma results. 
In this study, median log plasma HCV RNA value was 5.67 (interquartile range: 6.32-
5.03) log10 IU/mL and median log values of DBS (4ᵒC) HCV RNA and DBS (≥37ᵒC) 
HCV RNA 3.75 (interquartile range: 4.17-3.10) log10 IU/mL and 3.99 (interquartile 
range: 4.30-3.21) log10 IU/mL, respectively.  
A difference of 1.92 log10 IU/mL was observed between median log value of plasma 
HCV RNA and median log value of DBS (4ᵒC) HCV RNA. DBS at ≥37ᵒC showed 
slightly less difference of 1.68 log10 IU/mL between its median log HCV RNA and 
plasma log HCV RNA value. This was in accordance with results from previous 
published studies by Marins et al. (176), which showed 2 log10 IU/mL difference in 
plasma log10 HCV RNA and DBS log10 HCV RNA values and a study in France 
undertaken by Soulier et al. where mean HCV RNA level of DBS with whole blood 
was 1.75 ± 0.3 log10 IU/mL less than that of plasma (167). This signifies that DBS can 
be used as means of sampling for HCV RNA as the difference between plasma and DBS 
HCV RNA log10 values is consistent in different studies and DBS HCV RNA values 
can be utilised to predict the plasma HCV RNA value. 
There was strong correlation between HCV RNA log10 values of both, DBS at 4ᵒC (R= 
0.950, p<0.0001) and DBS at ≥37ᵒC HCV RNA log10 values (R= 0.943, p<0.0001) with 
that of the plasma log10 HCV RNA value, this again is in concordance with the 
published data. 
Bland-Altman analysis was also performed. As to show high agreement between two 
tests in Bland-Altman analysis, 95% of values should lie between -1.96 SD and +1.96 
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SD. The values of the DBS log10 HCV RNA and plasma log10 HCV RNA showed a 
high agreement between the results, in our study.  
Whole blood is spotted onto DBS while plasma is the preferred sample for testing of 
HCV RNA. There is difference in sample volume and sample type between plasma and 
DBS samples, which need to be adjusted for giving an accurate result. PCV values of 
samples are required for arriving at a correction factor, as is shown in studies by David 
et al. (171) and Marins S. et al. (176).  
In our study, DBS samples were normalised with respect to sample type and volume, 
by the use of a correction factor/normalisation coefficient (ascertained by median PCV 
value of study participants, 37.4%) and showed a reduction of 0.75-1.01 log10 IU/mL 
from that of plasma HCV RNA values, suggesting that there is some amount of loss in 
efficiency of amplification on using DBS samples, again in accordance with the finding 
in the study by Marins S. et al. (176). 
Sample with plasma HCV RNA value of 542 IU/mL (2.73 log10 IU/mL) was detected 
in both DBS at 4ᵒC and at ≥37ᵒC, with no value but <12 IU/mL detected in DBS kept 
at 4ᵒC and 26 IU/ml (1.46 log10 IU/mL) in DBS incubated at ≥37ᵒC.  
Another sample with plasma HCV RNA of 17 IU/ml (1.23 log10 IU/mL) was not 
detected in both of the corresponding DBS cards, showing the lower limit of detection 
of HCV RNA by DBS in our study to be around 542 IU/ml (2.73 log10 IU/ml). 
There have been a few studies which have assessed the lower limit of detection of HCV 
RNA by DBS. In a study by Tuaillon et al. the lowest limit of detection of HCV RNA 
by DBS was found to be 331 IU/mL (146). Bennett et al. came to a conclusion that for 
the HCV RNA to be detected in DBS, the value in corresponding plasma sample should 
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be between 150-250 IU/mL (179). Marques et al. and Mössner et al. found the lower 
detection limit of HCV RNA to be 58 copies/mL and <100 IU/mL, respectively 
(158,168). Thus, the lower limit of detection of HCV RNA in our study is higher than 
that found in other published studies. A study with a larger sample size is required to 
ascertain the limit of detection of HCV RNA in DBS samples accurately. 
HCV could not be genotyped in the DBS samples in our study using NS5b based 
sequencing method, which contrasts with the studies published by Tuaillon  et al. (146), 
Marques et al. (168), Solmone et al. (162), Hope et al. (180) Plamondon et al. (181) 
and Mahfoud et al. (182). In all these studies DBS samples were genotyped. Tuaillon 
et al. genotyped HCV by using Trugene HCV 5’ genotyping kit, Marques et al. and 
Plamondon et al. used Sanger sequencing targeting NS5b region while Solomone et al. 
and Mahfoud et al. genotyped HCV using line probe assays (146,162,168,181,182).  
The reason for none of the samples being genotyped by the in-house assay in our study 
may be its lower sensitivity compared to the commercial genotyping assay. The in-
house assay is a conventional PCR while the Abbott commercial assay for genotyping 
HCV was a real-time PCR. In addition, in-house genotyping assay has a lower limit of 
detection around 4 log10 IU/ml, which was the HCV RNA titre of DBS samples selected 
for genotyping, thus giving a negative result (183–185). 
Two paired DBS samples with viral loads of 4.05 log10 IU/mL (4ᵒC) and 4.04 log10 
IU/mL (≥37ᵒC) for the first sample and viral load of 4.84 log10 IU/mL (4ᵒC) and 4.93 
log10 IU/mL (≥37ᵒC) for second sample were genotyped by Abbott RealTime HCV 
genotype II assay. Genotype 1b and genotype 3 was detected for the first and second 
samples, respectively. The results were in conformity with that of the plasma 
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genotyping result. Abbott genotyping assay being a real time PCR has higher sensitivity 
and specificity and can detect genotypes in samples with lower viral loads, as is shown 
in studies by Nadiye et al. (lowest viral load genotyped: 2.85 log10 IU/ml) (186) and 
Sohn et al. (lowest viral load genotyped: 2.70 log10 IU/mL) (183). With the advent of 
pangenotypic drugs such as velpatasvir, sofosbuvir, voxilaprevir, glecaprevir and 
pibrentasvir, the role of HCV genotyping may be only for epidemiological purposes in 
the future (187,188). 
HCV core antigen is a structural protein of HCV which is detected in blood during viral 
replication. Its detection in blood is a cost-effective method to diagnose active HCV 
infection, as HCV RNA PCR is a costly and cumbersome procedure. It is present in 
blood during the pre-seroconversion period and can also be used as a marker of infection 
in neonates and immunocompromised individuals in whom antibody response is not 
reliable for diagnosis (189). 
HCV core antigen was also estimated in a total of 29 samples. As HCV core antigen 
estimation is easier and requires less equipment than HCV RNA analysis and still gives 
a clear indication about the infection, HCV core antigen estimation has the potential of 
being used as marker for screening and treatment response in low resource areas 
(18,189). DBS (4ᵒC & ≥37ᵒC) and plasma HCV core antigen values were poorly 
correlated (4ᵒC, r=0.31; ≥37ᵒC, r=0.16). This can be due to the prolonged storage of 
DBS samples at different temperatures for a period of 15 days, which might have led to 
deterioration of core antigen. HCV core antigen estimation was undertaken on DBS 
samples by Brandão et al. and they showed a deterioration in the OD values after storage 
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of DBS samples at -20ᵒC (164). Soulier et al. (167) also found that DBS had a poor 
sensitivity for quantifying HCV core antigen. Thus, our findings were corroborated. 
Our study has demonstrated that DBS can be used as an alternative to plasma for 
qualitative identification of HCV infection in resource-limited settings. The difference 
in DBS log10 values and plasma log10 values is in concordance with previous studies. A 
normalisation/correction factor needs to be deduced while dealing with DBS samples, 
as the sample volume in DBS is less than that of plasma used for testing and the fact 
that whole blood is spotted onto DBS which contains blood cells in addition to plasma. 
Genotyping of HCV requires a viral load of about 5 log10 IU/mL and samples with only 
very high viral loads can be genotyped by using DBS. The limitation of our study was 
the small sample size. A larger study is required for predicting the feasibility of DBS 
samples as an alternative to plasma, primarily for estimation of HCV core antigen. 
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CONCLUSION 
 
Suitability of dried blood spots (DBS) as a method of sampling, storage and 
transportation for detecting HCV RNA as a marker of current HCV infection was 
evaluated in our study. Viral loads from DBS samples correlated well with that of 
plasma, with findings being in accordance with previous studies.  
One of the objectives of our study was to evaluate the effect of temperature conditions 
prevalent in the Indian subcontinent on the dried blood spots. There was no significant 
deterioration of nucleic acids at a temperature ≥37ᵒC with the median log10 HCV RNA 
value (3.99 log10 IU/ml) of DBS samples being even slightly better than that of median 
log10 HCV RNA value (3.75 log10 IU/mL) of samples at 4ᵒC. This makes DBS a highly 
suitable means of sampling in tropical resource-limited centres. 
Genotyping of HCV was possible with the use of commercial HCV real-time PCR but 
not with our in-house genotyping assay using conventional PCR. HCV core antigen 
though detectable in DBS samples, showed a poor correlation with that of plasma 
samples. Larger studies are the need of the hour to evaluate feasibility of DBS in the 
Indian subcontinent, especially for estimating HCV core antigen. 
DBS can be used as an alternative to plasma for collection, storage and transportation 
of samples from resource-limited settings where there are no facilities available for 
diagnosing current HCV infection. Transport of DBS even in high ambient temperatures 
for over two weeks does not diminish HCV RNA titres significantly, making it an 
important alternative specimen in public health programmes. 
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ANNEXURE I 
           ABBREVIATIONS 
 
HCV                  Hepatitis C virus 
ELISA               Enzyme linked immunosorbent assay 
CMIA                Chemiluminescent microparticle immunoassay 
RDT                   Rapid diagnostic tests 
ORF                   Open reading frame 
IRES                  Internal ribosomal entry site 
PAMP                Pathogen associated molecular patterns 
RIG-1                Retinoic acid inducible gene-1 
IRF                    Interferon regulatory factor 
RNA                  Ribonucleic acid 
DAA                  Directly acting antivirals 
DBS                   Dried blood spots 
SVR                   Sustained virological response 
PCV                   Packed cell volume 
 
 
 
 
 
 
 
 
2 
 
ABSTRACT 
 
Introduction: There are 6-10 million HCV carriers in India, of whom many are 
unaware of treatment. With the availability of directly acting antivirals, there is 
possibility of cure. Confirmatory diagnosis of HCV infection (HCV RNA detection) is 
essential prior to starting therapy. HCV RNA detection is not available in many parts 
of India. Shipment of plasma from distant places to referral laboratory may affect HCV 
RNA titres. Dried blood spots (DBS) provide an easy alternative for transporting 
samples to centres where HCV RNA testing is done.  
 
Aims & Objectives: Evaluating DBS samples as feasible alternative to plasma for HCV 
RNA detection and HCV core antigen estimation. 
 
Materials & Methods: In this cross-sectional study, 40 consecutive patients’ blood 
samples were collected from patients referred from the Liver Clinic. Whole blood was 
spotted onto two Whatman 903 cards. One card was incubated at 37ᵒC and other at 4ᵒC 
for 15 days, after drying. DBS was eluted and run in Abbott Real Time HCV assay. 
HCV was also quantified using Abbott ARCHITECT HCV core antigen assay for 29 of 
study patients. Results were compared with normal plasma values. 
 
Results: The median log HCV RNA Value (MLHRV) in plasma was 5.67 while in DBS 
was 3.99 (37ᵒC) and 3.75 (4ᵒC); difference in plasma and DBS MLHRV values was 
1.68 (37ᵒC) and 1.92 (4ᵒC) logs, respectively. Interclass Correlation values were 0.943 
3 
 
(37ᵒC) and 0.950 (4ᵒC), showing high agreement. The median HCV core antigen value 
for plasma was 325.35 fmol/L, while it was 4.77 (37ᵒC) and 4.64 (4ᵒC) for DBS 
samples. 
 
Discussion and Conclusions: DBS can be used for sampling patients from distant 
resource-limited settings as an alternative to plasma for HCV RNA viral load 
estimation. Larger studies are required to evaluate feasibility of DBS in the Indian 
subcontinent, especially for role of HCV core antigen estimation. 
 
Key words: Hepatitis C virus, Dried blood spots, Directly acting antivirals 
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Figure 1.Virological and immunological markers in self-resolving HCV infection 
(23) 
 
 
Figure 2. Virological and immunological markers in chronic HCV infection (23) 
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   Table 1. Distribution of symptomatic and asymptomatic study patients 
 
 
    
  Table 2. Clinical profile of study patients 
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Table 3. Distribution of haematocrit values among study patients 
 
 
Table 4. Serum creatinine values of study patients 
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Table 5. Prothombin values of study patients 
 
 
Table 6. APPT values of study patients 
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Table 7. Plasma HCV RNA among male study patients 
 
 
Table 8. Plasma HCV RNA values among female study patients 
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